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Chapter I 
VASODILATION IN THE TREATMENT OF HYPERTENSION 
9 

INTRODUCTION 
It is well established that high blood pressure plays an im-
portant role in the development of cardiovascular disease (1). 
There is now good evidence that cardiovascular complications can 
be reduced by antihypertensive treatment (2,3,4). It is, there-
fore, important to search for effective antihypertensive treat-
ment protocols, hypertension occurs in 15-20% of all adults (5) 
and about 80-95% of these patients have essential or primary 
hypertension (5,6). The remaining patients have so-called secon-
dary hypertension and only a few forms thereof are amenable to 
definitive therapy. For example, screening for surgically curable, 
renovascular hypertension gives positive results in only 1% of all 
hypertensive patients (5,7). Thus most patients will depend on 
treatment with antihypertensive drugs which they usually have to 
take during the rest of their life. 
Nowadays, patients with mild and moderate hypertension are 
usually treated with diuretics, B-adrenoreceptor blocking drugs 
(ß-blockers) or combinations thereof (8,9). In most patients 
adequate control of blood pressure can be obtained with such 
regimens, while the incidence of side-effects is low. In 10-20% 
of the patients, mostly those who have marked and severe hyper-
tension, the response of the blood pressure to these drugs may 
be insufficient and additional treatment with other drugs will be 
necessary. Furthermore, a small group of patients (1%) presents 
with one of the forms of a hypertensive crisis: accelerated or 
malignant hypertension, or hypertensive encephalopathy (10). In 
these so-called hypertensive emergencies prompt lowering of the 
blood pressure is mandatory. Vasodilating agents are attractive 
both as a third category of drugs for chronic treatment and as 
drugs of first choice in hypertensive emergencies. 
Diazoxide is a highly potent vasodilating drug that has been 
used in our clinic since 1973 for the treatment of patients with 
severe hypertension (11). When given intravenously this drug can 
be used for the treatment of hypertensive crisis whereas it can 
also be used for long-term oral treatment. 
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The efficacy of diazoxide, its characteristics and side-
effects are the subject of tne studies presented in this thesis. 
VASODILATORS AND HYPERTENSION 
During the early stages of hypertension there is often an 
increase in cardiac output which is nearly always accompanied by 
ar increase in total peripheral resistance (12,13). Systemic 
haemodynamic studies at later stages in patients with established 
hypertension show that the cardiac output has returned to normal 
with a normal extracellular volume and plasma volume, whereas 
the total peripheral resistance has remained elevated (12,14). 
It seems logical, therefore, to treat hypertension primarily by 
attempts to normalize this increase in resistance by the induc-
tion of vasodilation. 
Theoretically all forms of hypertension should be treated in 
this way. However, from a practical point of view this is not 
very attractive, since the known vasodilating drugs must almost 
always be combined with other drugs to combat their undesirable 
effects. This will be discussed in the next section. Therefore, 
treatment is preferentially started with drugs that can be used 
alone. The initial approach is either an attempt to decrease the 
cardiac output with 3-blockers (9) or to decrease extracellular 
volume by diuretics (8). The latter group of crugs probably also 
decreases the peripheral resistance by a direct vasodilating 
action on blood vessels, but it is still not clear to what extent 
this effect contributes to their antihypertensive action (15). 
Thus, despite their theoretical advantages, the use of vaso-
dilators will be limited to the more serious stages of hyper-
tension. 
Various groups of drugs can induce vasodilation, but they are 
not all effective antihypertensive agents. In accordance with 
current use in the hypertension literature we define vasodilators 
as a category of drugs, that act by a direct relaxation of vas-
cular smooth muscle with consequent decrease in vascular tone 
(14,16). There are other antihypertensive drugs, whose effects 
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ultimately result in vasodilation, without being vasodilators in 
the strict sense. These drugs may act by a decrease in sympa-
thetic tone at different levels or by an indirect effect on 
vascular tone, for example via the renin-angiotensin system. 
Only the vasodilators, that have a direct influence on the vas-
cular tone, the so-called directly-acting vasodilators, are con-
sidered in this study. In table I the currently available drugs 
of this category are summarized. The nitrites (amyl nitrite) and 
sodium nitroprusside are the vasodilators that were discovered 
first. Their action is, however, very short, and sodium nitro-
prusside can only be administered intravenously. This makes these 
drugs unsuitable for the chronic treatment of hypertension. 
Nitroprusside is, however, a potent vasodilator and it has been 
succesfully used for the acute treatment of hypertensive crisis 
(17). Hydralazine was initially thought to act at the level of 
the central nervous system, but later on it was found to be a 
purely peripheral vasodilator (18). After initial enthusiasm it 
fell into disuse at later stages due to its troublesome side-
effects of palpitations and headache. However, the notion that 
these side-effects are caused by mechanisms compensatory to the 
vasodilatory action and that they can be obviated by complemen-
tary therapy has led to a revival in the use of this drug during 
the last decade (19). This new approach has also stimulated the 
search tor stronger acting vasodilators. It has resulted in the 
introduction of a number of highly active vasodilators that are 
suitable for long-term treatment of hypertension. Although all 
vasodilators induce a direct relaxation of vascular smooth muscle, 
there are quantitative differences as to their action on different 
types of vessels. As can be seen from table I most vasodilators 
act predominantly on the smooth muscles of the precapillary 
arterioles or resistance vessels, whereas especially nitrites 
and nitroprusside also act on the postcapillary veins or capa-
citance vessels. There seems to be an inverse relationship be-
tween the extent to which a drug acts on veins and the reflex 
increase in heart rate that will result from its action (20). 
This intriguing relationship has as yet not been fully explained. 
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TABLE X. Directly-acting úasodilatov drvgs 
Drug 
Nitrites 
Nitroprusside 
Hydralazine 
Diazoxide 
Minoxidil 
Guancydine 
Bupicomide 
Hydrazino-
pyndazine 
Tolnesoxide 
Nifedipine 
Mode of 
administration 
I.V. 
I.V. 
ι.v./p.o. 
i.v./p.o. 
p.o. 
p.o. 
p.o. 
1 . ν./p.о. 
i.v./p.o. 
p.o. 
Dose 
(mg/24 h) 
100 
0.03-0.15 
40-200 
300-600 
5-40 
100-1000 
900-2000 
5-90 
100-1200 
10-60 
potency 
++ 
+++ 
+ 
+++ 
+++ 
+ 
+ 
+ 
++ 
++ 
duration 
(hr) 
< 1 
< 1 
> 4 
> 8 
> 4 
> 8 
> 4 
> 4 
> 6 
> 4 
Activi ty 
arteries 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
veins 
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
heart rate 
-
+ 
++ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Vasodilators that are currently m use for long-term treatment 
all affect preferentially the resistance vessels. This leaves 
the sympathetically-mediated homeostatic reflex mechanisms at 
the venous side of the vascular system intact. Consequently, 
orthostatic or exercise-induced hypotension, which is an impor­
tant untoward effect of sympathicoplegic drugs, does not occur. 
This is illustrated in figure 1, in which the supine and standing 
mean arterial pressures (MAP), recorded during use of three dif­
ferent vasodilators are compared to those obtained during prazo­
sin, a post-synaptic a-adrenoreceptor blocking agent. The majority 
MAP (mmHg) ? 1 
—ι 1 1 \ -ι ι 1 1 1 1— 
100 120 140 160 8 0 Ю0 120 140 160 1Θ0 
MAP (mmHg) о < 
Fig. 1. Comparison of supine ( O — < ) and standing ( Τ ) mean arterial 
pressures (MAP) in hypertensive patients treated with hydralazine, 
diazoxide, minoxidil, or prazosin. 
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of patients on prazosin do have orthostatic hypotension, in con-
trast to the patients on the three directly-acting vasodilators. 
Another advantage of these vasodilators is inherent to their 
peripheral site of action: their vasodilating activity will be 
independent of the nature of the vasoconstrictive mechanism 
(catecholamines, angiotensin) that is causing the increase in 
peripheral resistance (14). 
The mechanism by ' hich these drugs induce relaxation of vas-
cular smooth muscle has not been completely clarified. The con-
tractile state of the smooth muscle cells is maintained or 
initiated tnrough calcium ion movements. It is likely that dia-
zoxide induces alterations of the calcium metabolism. 
HEMODYNAMIC CONSEQUENCES OF THE USE OF VASODILATORS 
Apart from diuretics, agents that interfere with sympathe-
tically mediated vasoconstriction have been the most widely 
prescribed antihypertensive drugs. This may seem remarkable in 
the light of their above-mentioned disadvantages. However, des-
pite its attractiveness on theoretical grounds, vasodilator 
therapy has been regarded relatively ineffective, because several 
compensatory mechanisms minimize its antihypertensive effect. 
The systematic study of Zacest et al (19) set out the lines along 
which one can cope with these compensatory reactions and it 
opened the way to an effective use of vasodilators in the treat-
ment of hypertension. 
Arterial pressure reduction by agents that act at the level 
of the precapillary resistance vessels will cause activation of 
baroreceptors resulting in an increase in sympathetic activity. 
This leads to an increase in heart rate and myocardial contrac-
tility and a decrease in venous capacitance. The consequent rise 
in cardiac output may counteract the vasodilator-induced hypo-
tensive effect up to 75% (14). Two other compensatory changes 
after blood pressure reduction by vasodilators are an increase 
of plasma renin activity (PRA) (21,22) and the renal retention 
of sodium and water (23,24). Figure 2, taken from a study of 
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Fig. 2. Consequences of direct vasodilation (according to Koch-Weser (14)). 
Koch-Weser (14) shows the interrelations between these three 
mechanisms and illustrates how they can reduce the hypotensive 
efficacy of vasodilator agents. 
The following series of observations in our patients will 
illustrate the importance of these compensatory mechanisms in 
clinical situations. Figure 3 shows the increases in heart rate 
in two groups of patients treated with minoxidil and diazoxide 
respectively. In many patients the tachycardia is an intolerable 
side-effect and a reason to discontinue the treatment despite 
a satisfactory control of the blood pressure (25). The figure 
also shows the effect of the addition of a ß-blocker (proprano-
lol) on heart rate. 
Most patients show an increase in PRA (figure 4). The stimulation 
of the renin-angiotensin system is a direct consequence of the 
decrease in blood pressure which leads to a diminished wall 
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heart rate (beats/mi η) 
120 
1 0 0 
8 0 -
120 
1 0 0 
8 0 -
minoxidi l 
η -13 
diazoxide 
η - 2 9 
before during during 
vasodilator vasodilator and 
propranolol ι ν ( 0 2nng/kg ) 
Fig. 3. Increases in heart rate during treatment with vasodilator drugs 
(minoxidil or aiazoxide) ana tne effects of the addition of 
propranolol mtravonously (0.2 mg/kg body weight) . Means + SEM 
are given. 
t e n s i o n i n t h e a f f e r e n t r e n a l a r t e r i o l e s w i t h c o n s e q u e n t s t i m u ­
l a t i o n of t h e v a s c u l a r r e c e p t o r s i n t h e j u x t a - g l o m e r u l a r 
a p p a r a t u s . This p r o c e s s i s f u r t h e r a m p l i f i e d by s y m p a t h e t i c 
s t i m u l a t i o n of t h e r e n a l nerves which form a d i r e c t s t i m u l u s 
for r e n i n r e l e a s e . The l a t t e r component of t h e r e n i n i n c r e a s e 
w i l l be b locked by some ß - b l o c k e r s ( p r o p r a n o l o l in f i g u r e 4 ) . 
F igu re 5 i l l u s t r a t e s t h e s e combined e f f e c t s of a B-blocker on 
h e a r t r a t e and PRA in a p a t i e n t in whom t h i s drug was a d m i n i s t e r e d 
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after treatment of a hypertensive crisis with an infusion of 
diazoxide. Heart rate and PRA had increased after diazoxide 
but both decreased again after administration of propranolol. 
The sodium and water retention that occur during vasodilator 
therapy are caused by a decrease m renal perfusion pressure, 
that results from the fall in systemic blood pressure. 
Furthermore the stimulation of the renin-angiotensin system 
causes sodium retention by an increased secretion of aldosterone. 
PRA 
(ng/10nnl/3h ) 
1000 
6 0 0 -
4 0 0 
200 
100 
60 
4 0 
20 
control during during 
diazcKide β blockade 
Fig. 4. Changes in plasma renin activity (PRA) measured before and 60 mm 
after an infusion of diazoxide (5 mg/kg body weight, 15 mg/mm) and 
30 mm after an intravenous injection of propranolol (0.2 mg/kg 
body weight) in nine patients. 
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Fig. 5. The effects of diazoxide and propranolol on MAP, heart rate and 
PRA in a patient with marked, essential hypertension. 
Figure 6 gives an example of the sodium retention and consequent 
weight gain in a patient who received diazoxide orally. The 
tendency to retain salt and water is more pronounced in patients 
with already compromised renal function. The extent of fluid 
retention is also dependent on the potency and the dose of the 
vasodilator used. Figure 7 shows that there is a significant 
correlation between daily dosage of the vasodilator minoxidil 
and the change in body weight (25). 
20 
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4 5 0 
blood pressure 240 
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120 
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Fig . 6. Sodium r e t e n t i o n during o r a l t reatment with diazoxide in a p a t i e n t 
with severe rena l impairment, due to chronic g lomeru lonephr i t i s . 
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Fig. 7. Relation between the increase in body weight and the daily dose of 
the vasocilator -nmoxidil in 20 patients. 
CONCLUSION 
The above-mentioned compensatory reactions to administration 
of vasodilating drugs make it clear that potent drugs of this 
class can only be used for chronic treatment of hypertension if 
they are combined with drugs that decrease cardiac sympathetic 
stimulation (i.e. ß-blockers) and with drugs that antagonize the 
fluid retention (i.e. diuretics). Since triple therapy is almost 
always required, vasodilating drugs are not the drugs of first 
choice in the treatment ot hypertension, although on theoretical 
grounds they would deserve such a position. Therefore, the use 
of vasodilators is for practical reasons in most instances post-
poned until treatment with diuretics and ß-blockers has proved to 
be insufficient for an adequate control of the high blood pressure. 
With tnis triple regimen, however, hypertension can be treated 
in almost all patients, independently of the degree, stage, or 
cause of their hypertensive disease. The absence of orthostatic 
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hypotension during treatment with vasodilators is a special ad-
vantage in comparison with regimens used previously and will 
result in a better patient compliance. 
The only situation, in which these vasodilating drugs can 
be used without addition of other agents, is in the treatment of 
hypertensive emergencies. As will be shown in the following 
chapters treatment schedules can be devised, which lead to prompt 
and safe control of blood pressure in patients with a hyperten-
sive crisis. 
23 
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Chapter II 
DIAZOXIDE: MODE OF ACTION, SIDE-
EFFECTS, AND PHARMACOKINETICS 

INTRODUCTION 
Although the antihypertensive efiect of the benzothiadiazines 
was discovered as early as 1957, their precise mode of action is 
still subject to discussion (1). The immediate antihypertensive 
effect of the thiazides has been ascribed to the urinary loss of 
sodium and the consequent decrease in plasma volume and cardiac 
output. The long-term antihypertensive effect of the thiazides 
on the other hand has been explained by the existence of a di­
rect vasodilating action. Some studies are in favour of this 
theory (2), others failed to show such an activity (3). In vitro 
experiments have shown, that benzothiadiazines can antagonize 
aortic contractions (4), suggesting a direct vascular effect of 
these drugs. On the basis of these findings attempts were made 
to synthetize benzothiadiazine analogues with a strong antihyper­
tensive and minimal diuretic activity (5). This was achieved by 
the removal of the sulphamyl group from the benzenoid moiety (6). 
The compound 7-chloro-3-methyl-2N-l,2,4-benzothiadiazine-l, 
1-dioxide (diazoxide) is a representative of this group of drugs. 
С ^ . Ν H 
NH H 2 N 0 2 S ^ ^ ^ \ S / O j 
Chlorothiazide 
02 
Diazoxide 
( 7-chloro-3-methyl-2N-
1,2,4-benzothiadiazine-l, 
Vdioxide) 
Fig. 1. Chemical structure of diazoxide and of chlorothiazide. 
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Figure 1 shows the chemical structure of diazoxide and for com-
parison the formula of chlorothiazide, one of the classic thia-
zides, is given. In a large number of experiments it was demon-
strated that diazoxide induced an immediate and prolonged decrease 
in blood pressure. The drug was not only devoid of diuretic effect, 
but on the contrary caused sodium retention (7). 
MODE OF ACTION 
The entrance of calcium into the cell and its release from 
intracellular calcium stores are important for the contraction of 
the smooth muscle cell. Since barium can induce smooth muscle 
contraction in a calcium-free environment in vitro, it was thought 
that it could replace calcium as a stimulus for contraction. 
Wohl et al (8,9,10J showed that the banurn-induced smooth muscle 
contraction or vasoconstriction was inhibited by diazoxide, and 
this suggested that the drug interfered with calcium metabolism. 
Three different mechanisms for this interaction were suggested: 
1. blockade of calcium receptors at the cell-menbrane (11), 
2. blockade of the calcium-release from the intracellular stores 
(12) , 
3. blockade at the level of the intracellular calcium receptors 
(13,14) . 
There is now evidence that barium does not actually replace cal-
cium, but that it acts by stimulation of calcium release from the 
intracellular stores. This makes it likely that diazoxide acts at 
the same level. Strong arguments for such a hypothesis stem from 
the recent worn of Siegers and his group. These experiments will 
be discussed in some detail in the next section. The arterial 
smooth muscle cells of hypertensive animals contain higher amounts 
of calcium and are hyperresponsive to different stimuli, caused 
by an increased efficiency to utilize calcium (8,9,10). This may 
explain why the action of diazoxide on the vessels of hyperten-
sive animals is stronger, than on the vessels of normotensive 
control animals. 
An alternative explanation for the hypotensive effect of 
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diazoxide was given by Moore (15), who found that diazoxide inhi­
bits the enzyme phosphodiesterase. The consequent increase in 
intracellular cyclic AI1P could be responsible for the vasodila­
tion. This explanation seems not very likely, since papaverine, 
that gives much larger increases of cyclic AMP (16), has such a 
weak vasodilatory action in vivo, that it is not suitable for 
antihypertensive treatment. Furthermore Siegers did not observe 
a rise of cyclic AMP levels in the cortices of rat kidneys after 
perfusion of the kidney with diazoxide (personal communication). 
DIAZOXIDE IN THE ISOLATED PERFUSED RAT KIDNEY 
A better insight into the mechanism of action of diazoxide has 
been obtained by the studies of Siegers and his coworkers, who 
have used the isolated perfused rat kidney as a model (17). They 
have developed an elegant perfusion system that has been described 
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Fig. 2. Studies in the isolated perfused rat kidney model (17,18). Blockade 
of the bariumchloride-mediated vasoconstriction by diazoxide 
(by courtesy of Siegers). 
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in detail (18). 
Figure 2 shows the effects of bariumchloride and diazoxide in 
this system. The experimental design is as follows: The experi-
ment is started while the renal perfusion flow (RPF) is kept 
constant at a rate of 15.0 ml per mm. Vasoconstriction is induced 
by the infusion of increasing amounts of bariumchloride. The in-
crease of the renal perfusion pressure (RPP) that follows is off-
set by artificial lowering of the RPF. Thus, the effects of dia-
zoxide on the RPP can be studied under conditions of increasing 
vascular resistance. The figure shows that diazoxide infusion 
induces an abrupt fall in RPP that is larger when the banum-
induced vasoconstriction increases. When the administration of 
bariumchloride is interrupted at the end of tne experiment a fall 
in RPP similar to that induced by diazoxide is found. The RPP can 
then be increased to its base level by raising the RPF to its 
initial rate of 15.0 ml per mm. This experiment demonstrates that 
diazoxide interacts with the barium-mediated contraction and that 
its action is stronger under conditions of increased vasocon-
striction. 
In analogous experiments, the calcium antagonist verapamil 
(11) reduced the barium-induced vasoconstriction to the same ex-
tent as diazoxide. Addition of diazoxide during verapamil did not 
result in a further decrease of RPP. These results are depicted 
in Figure 3. Thus, both verapamil and diazoxide seem to counter-
act the barium (or calcium)-mediated vasoconstrictor mechanism. 
Furthermore it was shown that after removal of calcium from the 
perfusion fluid, the vasoconstrictive response to barium was 
gradually reduced until it became ultimately negligible. This 
exhaustion phenomenon developed more slowly in kidneys of hyper-
tensive rats. Based on these experiments it was concluded that 
1. barium itself cannot replace calcium in the contractile pro-
cess, 2. barium stimulates intracellular stores to release cal-
cium, 3. vascular smooth muscle cells of hypertensive rats 
contain more intracellular calcium stores or sequester more cal-
cium into the available stores, as compared to the smooth muscle 
cells of normotensive rats. The fact, that hypertensive patients 
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Fig. 3. Tne effect of diazoxide on bariumcnloridc-mediated vasoconstriction 
in the isolated perfused rat kianey. Diazoxide cannot induce further 
vasodilation in the presence of verapamil (by courtesy of Siegers). 
as well as hypertensive animals demonstrate a greater response to 
diazoxide, than normotensive controls does support the latter con­
clusion. Concerning the mode of action of diazoxide three findings 
are relevant. First, if the isolated kidney is perfused with 
procaine, a short contraction is observed immediately after dis­
continuance of the procaine perfusion. This contraction cannot 
be blocked by diazoxide and this makes it unlikely that diazoxide 
acts directly on the contractile mechanism. Second, when the 
calcium stores are first exhausted by repeated barium stimulation 
under calcium free perfusion conditions, then the subsequent re­
loading of these stores is not blocked by diazoxide. This obser-
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vation suggests that diazoxide does not interfere with the 
calcium influx across the smooth muscle cell membrane and is 
therefore not a true calcium antagonist. Third, it could be shown 
that diazoxide and barium interact in a non-competitive manner 
(figure 4). This suggests that barium and diazoxide do not act 
at the same receptor site. Several reports in the literature 
mention the finding of a competitive antagonism between barium 
and diazoxide. Differences in the animal models used may be res­
ponsible for these discrepancies. Although further studies are 
necessary it may be safely concluded from the available data that 
the vasodilatory effect of diazoxide is not mediated by humoral 
or sympathetic mechanisms, but by a direct inhibition of the 
calcium mediated vasoconstriction. 
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Fxg. 4. Demonstration of the non-competitive antagonism between bariun and 
diazoxide (by courtesy of Siegers). 
EFFECTS OF DIAZOXIDE ON RENAL FUNCTION AND RENAL HAEMODYNAMICS 
The initial reports on chronic treatment of severe hypertension 
with diazoxide stated that renal function sometimes improved (19), 
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Serum creatinine levels during chronic use of oral diazoxide. 
Inititially the serum creatinine increases but then gradually returns 
to the values before institution of diazoxide despite an important 
and stable decrease in blood pressure. 
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although in a later study this appeared to hold true only for 
patients with essential hypertension (20). We have never observed 
such an improvement in the more than 100 patients, whom we have 
treated. By contrast, in most patients renal function declined, 
especially when it was already impaired at the start of treatment. 
It is therefore important to assess whether diazoxide has a di­
rect nephrotoxic effect. We found that the decrease in renal 
function is always reversible alter discontinuation of dia70xide 
(21). There is, furthermore, a correlation with the initial 
change in blood pressure. Figure 5 shows the decrease in renal 
function in a patient with severe hypertension and seriously im­
paired renal function. Treatment with diazoxide effectively 
lowered the blood pressure with a concomitant increase in serum 
creatinine. Although dia/oxide is continued and blood pressure 
remains under control, tne creatinine returned gradually to its 
initial values. We have observed this phenomenon in several pa­
tients. Figure 6 shows that there was a significant correlation 
between the increase in creatinine and the decrease in the cal­
culated mean arterial pressure. These observations suggest that 
Δ serum creatinine (·/·) 
60 
60 40 
Δ МАРС/.) 
Fig. 6. Correlation between the increase in serum creatinine and the decrease 
in MAP during chronic treatment with oral diazoxide. 
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the decrease in blood pressure governs the charges in renal 
function, probably by interference with renal perfusion. Clini­
cal studies of renal function during diazoxidc with more sophis­
ticated measurements of effective renal plasma flow (ЬКРГ) and 
glomerular filtration rate (GrR) are scarce. A decrease in both 
ERPF and GïR occurs imnediately after diazoxidc administration 
(22,23), whereas measurements after some hours or days show an 
increase or no change in both parameters (22,24). In animal ex-
periments most authors observed a decrease in LRPF without 
concomitant changes in GFR (25,26). however, when diazoxide was 
in]ected directly into the renal artery, a minor increase in 
GFR was found (27,28). 
Taken together these observations make it hignly unlikely that 
diazoxide has a direct nephrotoxic effect. In most patients, 
after an initial decrease, renal function returns to its initial 
level, despite a permanent decrease in mean arterial pressure of 
20-30 percent. Only in exceptional cases of severely impaired 
renal function or sudden and large decreases in blood pressure, 
the kidney apparently cannot compensate for the decreased per-
fusion pressure and consequently renal function deteriorates 
further during the treatment with diazoxide. 
Diazoxide causes retention of sodium and water m almost all 
patients who receive the drug. The occurrence of overt edema is 
not infrequent. Some authors have assumed that this phenomenon 
was caused by a direct effect of diazoxide on the renal tubule 
(25,26). This seems not very likely since the drug shares the 
sodium-retaining property with many other, chemically unrelated, 
vasodilators (26). On the other hand there is evidence for a 
relationship with changes in renal haemodynamics. A fall in renal 
perfusion pressure will stimulate the renm-angiotensin-aldosteron 
system and cause an increased sodium reabsorption in the distal 
tubule. Furthermore, in experimental animals the retention of 
sodium and water after systemic administration of diazoxide, 
occurred together with decreases in renal function (25,26). The 
decrease in renal perfusion pressure that follows vasodilation 
may lead to impaired sodium excretion via a fall in glomerular 
filtration rate. 
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As discussed in the previous section, the decrease in renal per-
fusion is not always acconpanied by a decrease in GTR. Under such 
circumstances an increase in filtration fraction will occur with 
consequent enhancement of the retention of sodium and water. 
This explains why patients in whom the GFR remains unchanged 
after institution of diazoxide treatment, nevertheless develop 
sodium retention. The sodium retaining tendency by itself, does 
not explain, however, why most ot the patients develop overt 
edema. In comparable situations of decreased perfusion pressure 
(e.g. bilateral renal artery stenosis) or primarily increased 
tubular sodium reabsorption (primary hyperaldosteronismj edema 
does not develop. Retention of salt and water under these cir-
cumstances leads to extracellular volume expansion with a conse-
quent "escape" from the sodium retaining factors. If diazoxide 
only interfered with renal haemodynamics, a similar escape-mecha-
nism might be expected. The most attractive hypothesis on edema-
formation during vasodilator therapy has been put forward by 
Thurston et al {29l. Vasodilation of the arterioles, without 
great changes in the tone of capacitance vessels, causes an in-
creased hydrostatic pressure in the capillary bed. According to 
Starling's mechanism the balance between intravascular pressure 
(hydrostatic pressure minus oncotic pressure) and tissue pressure 
will be disturbed with consequent transsudation of fluid into 
the interstitial space. In this view edema formation is the 
primary event and the retention of sodium and water is secondary 
to this. The condition thus is more or less comparable to that 
of patients with a nephrotic syndrome in whom the decrease in 
oncotic pressure is the primary cause for edema formation. The 
absence of a direct effect of diazoxide on the kidney is also 
apparent from observations from Siegers' group (18,30) in the 
isolated perfused rat kidney. In figure 7 the effects of dia-
zoxide and hydrochlorothiazide are compared. Whereas the diuretic 
drug hydrochlorothiazide causes significant increases in diure-
sis, GFR and sodium and potassium excretion, the experiments in 
which diazoxide is used do not differ from those with control 
kidneys. In these experiments it could also be demonstrated, 
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В diazoxide 
Ш hydrochlorothiazide 
F i g . 7. Studies in the i s o l a t e d perfused r a t kidney. Effects of diazoxide and 
hydrochlorothiaz ide on u r i n e volume (V), glomerular f i l t r a t i o n r a t e 
(GFR) and on the excre t ion of sodium (Na) and potassium (K). There 
are no s i g n i f i c a n t d i f ferences between diazoxide and c o n t r o l exper i­
ments (by courtesy of S i e g e r s ) . 
t h a t t h e p r e v i o u s l y r e p o r t e d n a t r i u r e t i c e f f e c t s o f d i a z o x i d e i n 
i s o l a t e d p e r f u s e d k i d n e y s ( 2 7 , 2 8 ) p r o b a b l y w e r e c a u s e d by s o d i u m 
h y d r o x i d e , u s e d a s a s o l v e n t f o r t h e d r u g ( S i e g e r s , p e r s o n a l 
c o m m u n i c a t i o n ) . 
OTHER EFFECTS OF DIAZOXIDE 
A p a r t f rom i t s a n t i h y p e r t e n s i v e e f f e c t s d i a z o x i d e h a s some 
o t h e r p r o p e r t i e s , t h a t may c a u s e u n w a n t e d ( s i d e - ) e f f e c t s . The 
m e t a b o l i c c h a n g e s a n d s i d e - e f f e c t s i n d u c e d by d i a z o x i d e a r e 
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summarized in table I. The most important of these is the inhi-
bition of insulin release, which causes an increase in glucose 
levels and sometimes diabetic coma, either of ketoacidotic (51) or 
of hyperosmolar type (52) . The increase in catecholamines and the 
inhibition of glucagon secretion contribute to the hyperglycaemic 
effect (53). The high incidence of hyperglycaemia has limited the 
application of the drug for chronic oral treatment. Figure 8 shows 
the effects of intravenously administered diazoxide on insulin, 
glucose and free fatty acids in some of our patients. 
Fig. 8. Concentrations of insulin, glucose and free fatty acids (FFA) before 
(b) and after (a) intravenoas diazoxide administration. 
When diazoxide is used for chronic treatment, regular measure-
ments of blood glucose levels are indicated. In some patients 
restriction of the intake of simple sugars or oral hypoglycaemic 
agents must be prescribed. It is of interest that tolbutamide 
specifically antagonizes the effect of diazoxide on insulin re-
lease (54). In our experience almost all patients with a diazoxide-
induced diabetes can be treated with 500-1000 mg tolbutamide 
daily, without further (dietary) measures. Some patients require 
only temporary treatment and blood glucose levels remain normal 
after discontinuation of tolbutamide. We have never observed 
haematological side-effects, nor extrapyramidal disorders or 
pancreatitis, although we have used the drug in over 100 patients 
and m some of them for more than 5 years. 
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TABLE ι. Metabolio changes ar.d siae-effeoLt· of d-iazoxide 
Decrease or inhxbition 
Increase or stimulation 
Side-effects 
insulin secretion 
glucagon secretion 
Cortisol secretion 
thyroid iodine uptake 
immunoglobulin levels 
glucose 
free fatty acids 
catecholamines 
renin-secretion 
hypertrichosis 
rash, allergy 
haematological side-effects 
(thrombocytopenia, neutropenia, 
haemolysis) 
extrapyramidal disorders 
pancreatitis 
References 
31, 
32, 
34 
35 
36 
31, 
38, 
40 
41, 
44, 
46 
32 
33 
32, 
39 
42, 
45 
3/ 
43 
46, 47, 48 
49 
50 
TABLE I I . FurÜier indications for the use of diazoxide 
Mechanism Indication Reference 
inhibition of insulin secretion hypoglycaemia 
dumping 
familial periodic hypokalaemia 
55,56 
57 
58 
uterine relaxation 
hypotensive action 
stimulation of renin secretion 
inhibition of labor 
primary pulmonary hypertension 
diagnosis of renovascular hypertension 
5 9 , 6 0 
6 1 , 6 2 
6 3 , 6 4 
sodium retention salt-losing renal disease 65 
anti-diuretic thirst, diabetes insipidus 
polyuria 
66,67 
68 
Diazoxide is also used for indications other than systemic 
hypertension and these are, together with the relevant literature, 
listed in table II. Advantage has been taken from its hypergly-
caemic effect to treat some forms of hypoglycaemia. The relaxa-
tion of the smooth muscles is not confined to the vascular smooth 
musculature. In experimental studies a relaxant effect on ureteral 
(69), intestinal (70) and uterine (71) smooth muscles has been 
described. The latter observation has led to the use of diazoxide 
for uterine relaxation, for example, in premature labor or immi-
nent abortion. 
PHARMACOKINETICS OF DIAZOXIDE 
In 1973 Sadee et al (72) developed a sensitive and reliable 
method for the determination of diazoxide in blood and urine, 
based on gas chromatography-mass spectrometry. Using gas chroma-
tography with nitrogen detection Fleuren and van Rossum developed 
a sensitive method for the determination of some thiazides (73) 
and this mode of detection was successfully applied to diazoxide. 
Figure 9, for instance, shows a plasma disappearance curve after 
intravenous administration of diazoxide. Both methods are, how-
ever, time-consuming. Furthermore, before the gas chromatographic 
analysis, diazoxide has to be derivatized with diazomethane, a 
very toxic compound. Vree et al (74) have subsequently developed 
a relatively simple and quick method by using high pressure 
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Fig. 9. Concentration-time plot of diazoxiae administered as a slow infusion 
(rate 15 mg/min, dose 5 mg/kg body weight). 
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liquid chromatography (HPLC). 
Figure 10 shows that there is a good correlation between the 
results obtained with the two methods. 
~i 1 1 1 1 rlh-1-^ 
20 40 60 100 
diazoxide HPLC ( mg/1 ) 
Fig. 10. Determination of diazoxide in plasma. Correlation between the dé-
terminations by gas chroiiatography (GLC) and Dy high pressure liquid 
chromatography (HPLC). The dotted line reoresents the line of 
equality. The solid line is the linear regression with a slope of 
0.99. 
In t h i s s e c t i o n we w i l l b r i e f l y d i s c u s s t h e g e n e r a l pharmaco-
k i n e t i c q u a l i t i e s of d i a z o x i d e based on our own e x p e r i e n c e and 
d a t a from the l i t e r a t u r e . 
Absorp t ion and d i s t r i b u t i o n : Af t e r o r a l i n g e s t i o n d i a z o x i d e 
i s r a p i d l y absorbed and in n e a r l y a l l p a t i e n t s t h e r a p e u t i c l e v e l s 
(above 10 mg/1) a r e r e a c h e d , when adequa te doses a r e used (5 mg/ 
kg body w e j g h t ) . A f t e r i n t r a v e n o u s bo lus a d m i n i s t r a t i o n of 300 mg 
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diazoxide we have observed peak plasma levels of up to 75 mg/1. 
The post-distribution levels amount 15 to 25 mg/1 (72), which xs 
in the same range as after oral administration. This level is 
also reached after slow infusion of diazoxide (5 mg/kg body weight), 
as is shown in figure 9. The curve shows a redistribution phase 
which lasts between 0.5 and 2 hours. Thereafter the elimination 
follows a monoexponential decay, which is apparent from the 
linearity of the last part of the semi-logarithmic concentration-
time plot. The volume of distribution is relatively small and 
varies from 20-33% of the body weight (Table III). This is in 
accordance with literature data (72,76,77). 
Plasma half life: In Table III the half lives in three normal 
individuals and five hypertensive patients are given. Although 
in patients with renal failure an important increase of plasma 
half life has been reported (using the spectrophotometnc method) 
(78), recent studies, using more reliable methods, could not 
confirm this (72,79). Our results also fail to show a correla-
tion between creatinine clearance and elimination rate. Magni-
tude of blood pressure reduction does not correlate with the 
plasma levels and the half life greatly outlasts the hypotensive 
effect. 
Protein binding: In the circulation diazoxide is highly bound 
to plasma albumin (90 to 95%) (76). Patients with impaired renal 
function often have low albumin levels and consequently higher 
levels of free diazoxide (75,80). Pearson et al (75) found a 
correlation between plasma urea and both the percentages of free 
diazoxide and the hypotensive effect. 
14 Metabolism and excretion: Studies with C-diazoxide (81) 
clearly indicate that 70-80% of the drug is metabolized, whereas 
nearly all of the remainder is excreted into the urine. The meta-
bolites are cleared largely by the kidney and in a small proportion 
via bile and faeces (81). The metabolites are protein-bound, but 
they do not displace diazoxide from its protein-binding sites. 
They are devoid of cardiovascular activity (5). 
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TABLE ill. Pharmaookinetia data of diazoxide in noimotensive conbvols (A-C) 
and in hypertensioe patients (D-Η) using H.P.L.C.** 
Endogenous 
Sex Age Creatinine creatinine 
(yrs) (μΜ/l) clearance 
2 (ml/min/1.73m ) 
Dose and mode Blood tb 
Total 
body Renal 
of administration pressure (hr) (1) clearance clearance 
(ml/nun) (mmHg) 
normal 
normal 
normal 
190/124 
200/120 
168/106 
178/132 
128/95 
20 
17.5 
16 
18 
1/ 
15.5 
21 
22 
38 
18 
30 
53 
40 
23 
14 
17 
20* 
25 
15 
24* 
19 
16 
(ml/min) 
13.1 
9.4 
12.3 
12.8* 
1/.2 
11.1 
13.1* 
10.1 
4.5 
Diazoxide 
in urine 
A M 
в M 
с M 
33 
35 
31 
D 
E 
F 
G 
II 
M 
F 
M 
F 
M 
61 
54 
42 
37 
37 
87 
87 
69 
100 
100 
232 
81 
85 
120 
110 
162 
89 
66 
55 
108 
107 
100 
100 
200 
100 
25 
100 
100 
100 
420 
300 
410 
300 
405 
mg 
mg 
mg 
mg 
mg 
mg 
mg 
mg 
mg 
mg 
mg 
mg 
mg 
1, 
1 
1, 
P· 
1 
1, 
P· 
1, 
1, 
1, 
1. 
1. 
1. 
.V 
. V 
. V 
.o 
.V 
.V 
.o 
.V 
. V 
.V 
. V 
. V 
.V 
2.3 
1.7 
2.5 
3.2 
5.2 
2.0 
3.2 
2.1 
14.6 
16.2 
20.4 
22.6 
27.8 
23.5 
23.5 
18.6 
0.8 16.3 
Approximations because of unknown bioavailability. 
Abbreviations: HPLC: high pressure liquid chromatography, V¿J: volume of distribution (calculated as 
Vd = 1.44 χ tb x -rj—· wherein D means dose and AUG the area under the curve). 
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SUMMARY 
The potent vasodilating drug diazoxide (Hyperstat) was admin-
istered by fast bolus injection in 27 hypertensive emergencies in 
24 patients. The antihypertensive effect was strong, occurred 
immediately after the injection, and lasted for about 8-10 hours. 
The blood pressure reduction was 25-30% after 10-20 minutes. 
Symptoms of hypertensive encephalopathy disappeared immediately 
in most instances. Only a few patients complained of nausea, vomi-
ting or palpitations. One patient developed a slight hypotension. 
With only a few exceptions there was a decrease in renal function 
and a rise of the blood sugar. Diazoxide is a useful contribution 
to the therapeutic approach of the hypertensive emergency. 
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INTRODUCTION 
The so-called "hypertensive crisis" is a life-threatening 
situation, which makes immediate reduction of the blood pressure 
mandatory, irrespective of the cause of the hypertension (12,13). 
In the past, treatment has consisted of intramuscular administra-
tion of reserpine, but the onset of action of this agent is too 
slow and its effect often insufficient. Furthermore, the reduc-
tion of the blood pressure by reserpine is frequently accompanied 
by dullness and mental depression. Although the ganglion blocking 
drugs (mecamylamine hydrochloride, pentolinium tartrate, tn-
methaphan camsylate) and the post ganglionic adrenergic neuron 
blocking drugs (guanethidine, debnsoquine, bethanidine) reduce 
blood pressure rapidly and effectively, they have undesirable 
side-effects, especially orthostatic hypotension. This jeopar-
dizes renal function, especially when it is already compromised. 
The introduction of directly-acting vasodilators, such as 
hydralazine, and of the more potent agents diazoxide and sodium 
nitroprusside has increased the possibilities for an immediate 
and effective reduction of the blood pressure. Diazoxide is an 
especially attractive drug, because its intravenous infection can 
cause a rapid blood pressure reduction within a few minutes, that 
lasts for about 6 hr. In the United States and England diazoxide 
has become more and more the drug of first choice in the treat-
ment of patients with a hypertensive crisis (2,3,4,6,7,14,17). 
In the Netherlands the drug was recently registered for this in-
p 
dication (Hyperstat ) and, therefore, it seemed useful to report 
here our experiences with this form of treatment. 
PATIENTS AND METHODS 
Since 1973,27 hypertensive crises in 24 patients (13 females 
and 11 males) were treated with diazoxide, which was administered 
via a rapid intravenous or so-called "bolus" infection. The mean 
age of the patients was 37 + 14 years (range 19-63 years). In 
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accordance with Kaplan (10) we diagnose patients as having a 
hypertensive crisis, when the following criteria have been met: 
1) Malignant hypertension (diastolic blood pressure above 130 
mntflg and papilledema) 
2) Accelerated nypertension (diastolic blood pressure above 130 
mmHg together with cotton wool exsudâtes or hemorrhages in the 
optic fundi) 
3) Signs and symptoms of a hypertensive encephalopathy (headache, 
loss of consciousness, seizures, epileptic state). 
Of the 24 patients, 12 suffered from malignant hypertension, 
seven from accelerated hypertension and five from hypertensive 
encephalopathy. Eleven patients had essential hypertension, where-
as in 13 it was of renal origin (five patients with transplant 
rejection, four with glomerulonephritis and two with renal artery 
stenosis). Seven patients showed seizures and seven had loss of 
consciousness. The retinal changes were classified according to 
Keith et al (11). In 16 patients a hypertensive retinopathy 
grade III or IV was diagnosed. In the five patients with a hyper-
tensive encephalopathy only minor symptoms of retinopathy were 
seen (grade I). In three patients funcoscopy was not performed. 
The diagnosis of left ventricular hypertrophy (LVH) was based on 
the electrocardiographic criteria from Estes (5). According to 
these criteria 14 patients showed a "definite" LVH, whereas in 
six patients a "probable" LVH was diagnosed. Two patients suf-
fered more than once from a hypertensive crisis. 
Blood pressure was measured with a legally stamped sphygmo-
manometer (Erkameter 300) in 13 patients and with an automatic 
blood pressure device (Artenosonde 1217, Roche) m 11 patients. 
After at least 3 blood pressure measurements diazoxide was ad-
ministered intravenously as a rapid injection (within 10 seconds). 
Thereafter, blood pressure was measured every 1 to 2 min during 
the first 30 m m and with a decreasing frequency afterwards. 
Dependent upon the severity of the situation a second rapid in-
jection of diazoxide was given when 1-2 hr after the first in-
jection the blood pressure reduction was insufficient. Sometimes 
3 or more injections were required before a satisfactory reduction 
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of blood pressure was obtained. The blood pressure lowering 
effect was evaluated by comparing the mean of at least 3 blood 
pressure readings before the infection with the mean of 3 values 
at 10-20 min and at 8-10 hr. The maximal decrease in blood pres-
sure which was usually reached at 3 to 5 min after the injection, 
was not included in the assessment, because this effect lasts 
only a few minutes, whereas mostly 10 m m after the administra-
tion a more constant blood pressure level has been reached (13). 
The mean arterial pressure (MAP) was calculated as the sum of the 
diastolic and one third of the pulse pressure. Before the first 
injection of diazoxide, and on the following morning (8-18 hr 
after injection) blood was withdrawn for determination of elec-
trolytes, glucose, urea and creatinine. 
Statistical analysis was performed using the Wilcoxon test for 
paired observations and the Spearman-rank-correlation coefficient 
(r). Differences were considered to be significant when P-levels 
were less than 5 percent. 
RESULTS 
In the Figures 1 and 2 representative examples of the rapid 
blood pressure reduction obtained by diazoxide are shown. In the 
patient in Figure 1 blood pressure was measured with the sphygmo-
manometer. There is a large blood pressure decrease within a few 
minutes, that is followed by a slight increase, until a more or 
less constant level is reached at about 10 min after the in-
jection. In the following hours blood pressure gradually rises 
but after 5 hr there still remains an antihypertensive effect. 
In figure 2 an example of an automatic blood pressure registration 
is shown in another patient. The first injection of diazoxide 
resulted in only a small reduction of the blood pressure, possi-
bly because the injection of diazoxide was given too slowly. 
Seven hr later a second injection induced a reduction of blood 
pressure to almost normal levels. The decrease of the blood pres-
sure in the whole group is shown in Table I. A mean of two in-
jections of diazoxide were administered(range 1-6). In 14 patients 
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220-
RR 
(mm Hg) 
180-
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100-: 
Fig. 1. Hypotensive effect of intravenous diazoxide in a patient with a hyper­
tensive crisis (sphygmomanometer measurements). 
mènjtes 'lou'-s 
0 20 40 60 2 4 6 
mnc t« hd^rs time otter mject'on 
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300 mg diozoxide г 300 mg diozoxide ι 
Fig. 2. Hypotensive effect of intravenous diazoxide in a patient with a hyper­
tensive crisis (automatic blood pressure measurements). A satisfactory 
blood pressure reduction is obtained only after the second injection. 
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Fig. 3. Decreases of the mean a r t e r i a l pressures (MAP) after intravenous 
administration of diazoxide in 27 hypertensive cr i ses . Individual 
values and means + SEM are given. 
r e s u l t s a r e a l s o shown i n f i g u r e 4. There was a mean, s i g n i f i c a n t 
i n c r e a s e of 30%. The h i g h e s t v a l u e s were observed i n two p a t i e n t s 
who had a l r e a d y an abnormal g l u c o s e t o l e r a n c e . No s i g n i f i c a n t 
changes were seen i n t h e e l e c t r o l y t e c o n c e n t r a t i o n s . The b i c a r b o ­
n a t e c o n c e n t r a t i o n t e n d e d t o f a l l somewhat from 2 4.7 + 3.6 t o 
23.6 + 3.6 mM/1 (p = 0.09) which i s p r o b a b l y r e l a t e d t o t h e i n ­
d u c t i o n of uremic a c i d o s i s by t h e d e c r e a s e i n r e n a l f u n c t i o n . 
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TABLE ι. ? f f eat of гирга injections of aiazoxide on eye tolte ana агаьіоіг* 
ùlooj presaure in 2/ hypertcnniJe arises in ?4 раігепъв 
Tine 
Before diazoxxde 
injection 
10-20 rain after 
injection 
8-10 hr after 
injection 
Systolic 
(imHg)* 
227 + 34 
170 + 25 
164 + 32 
Blood 
Decrease 
•! 
25.1 
27.8 
pressure 
Diastolic 
(mnHg)* 
143 + 19 
98 + 11 
103 + 15 
Decrease 
% 
31.5 
28.0 
Means + SD are given. 
a single injection was sufficient. The decreases in blood pres­
sure amount 25-30% for both the systolic and the diastolic 
pressure. The reduction of the MAP is shown in figure 3. All but 
one patients responded to the treatment. In the one non-responder 
the effect was still insufficient after four injections and, 
therefore, treatment with sodium nitroprusside was started after 
10 hr. 
The changes in serum creatinine concentration after diazoxide 
could be followed in 24 treatment periods. In 17 patients renal 
function was already decreased before treatment. Two patients 
were on chronic hemodialysis. Figure 4 shows that the creatinine 
increased m almost all instances. The mean increase was 49% and 
this was significant. The same held for the urea levels. There 
was a significant correlation between both increases (r = 0.83). 
Blood glucose levels after the injection of diazoxide were al­
ways determined in blood taken from the fasting patient. Tne 
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Fig. 4. Changes in the concentrations of serum creatinine, serum urea, and 
blood glucose after intravenous admnistration of aiazoxide. 
The treatment was well tolerated by all 24 patients. Only 4 
patients had temporary complaints of nausea and vomiting after 
the injection. Several other patients were already vomiting before 
diazoxide treatment, as a consequence of their encephalopathy. 
In most patients with hypertensive encephalopathy the symptoms 
and signs disappeared immediately after the injection. In two 
patients, who were already comatose during a few days at the time 
of their admission, the coma persisted. Both died a few days 
later, in spite of a good blood pressure control. Only one pa­
tient had transient hypotensive complaints; he became pale and 
clammy and felt dizzy. The lowest blood pressure measured was 
130/75 mmHg. His complaints disappeared spontaneously without 
measures to raise the blood pressure. Two patients complained 
of palpitations, which quickly disappeared after administration 
of propranolol. 
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DISCUSSION 
Diazoxide is a benzothiadiazine derivative without natriuretic 
action (16). It even causes sodium retention. Diazoxide induces 
vasodilation by a strong relaxation of the smooth muscles m the 
vascular wall, especially of the precapillary resistance arteri-
oles. It is assumed that this relaxation takes place via a 
blockade of the calcium receptors (21,22). This results in an 
impressive reduction of the peripheral resistance (1) and the 
blood pressure decreases. Because diazoxide has no influence on 
the vascular tone of the postcapillary capacitance vessels (20), 
it does not induce venous pooling, and thus orthostatic hypo-
tension does not occur. Pharmacokinetic studies show that over 
90% of diazoxide is bound to protein and that this fraction pro-
bably lacks pharmacologic activity. This implies that, for an 
effective action, as much free diazoxide as possible should 
reach the receptors before the binding to protein can take place. 
Therefore, a very rapid injection is thought to be of great im-
portance (18). It is almost always possible to inject the drug 
intravenously within 10 seconds and even in 4 to 6 seconds when 
the diameter of the intravenous cannula is large enough. One 
should avoid extravasation, since the alkaline injection fluid 
(pH = 11.5) can be very painful. When administered intravenously, 
the drug acts so rapidly and strongly that hypotension and shock 
may occur in the first minutes. In our patients we never observed 
shock and only one patient had complaints of hypotension. 
In case of protracted or progressive hypotension after administra-
tion of diazoxide, treatment with sympathicomimetic drugs may be 
necessary. The best approach is then to administer noradrenaline 
(4 yg/ml) or metaraminol (100 ug/ml) via a drip infusion under 
careful monitoring of the blood pressure. The concentration of 
these drugs in the infusion fluid can be raised if necessary. 
When diazoxide is used, sympathicomimetic drugs should always 
be at one's immediate disposal. 
Diazoxide lowers both systolic and diastolic blood pressure 
by 25 to 35%. There are indications that it is not effective m 
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a pheochromocytoma-induced hypertensive crisis (15). The treat-
ment can be continued in the course of the next hours with oral 
antihypertensive drugs. We then mostly use a combination of oral 
diazoxide and ß-adrenergic blocking drugs (propranolol, meto-
prolol). Later on the dose of these drugs can be lowered, appa-
rently because the treatment of the hypertensive crisis has 
interrupted a vicious circle (8). Only a single patient was 
resistant to diazoxide. Subsequently, her blood pressure respon-
ded to sodium nitroprusside. A disadvantage of the otherwise 
very effective drug nitroprusside is its very rapid and short 
action, that makes careful titration of the dose and continuous 
monitoring of the blood pressure necessary. The powerful and 
steep reduction of the blood pressure after diazoxide may induce 
a further decrease of the renal function, that often is already 
compromised. In accordance with most investigators we observed 
a significant increase of the creatinine and urea concentrations. 
Only Finnerty et al (8) and Broch-MjZller et al (2) have reported 
studies, wherein such an increase is absent. Although the crea-
tinine concentration increased significantly, we did not find a 
significant correlation between this increase and the decrease 
of the blood pressure, as was demonstrated by Johnson (9) in 
animal experiments. It is not entirely excluded, although unlikely, 
that diazoxide has a direct nephrotoxic effect. In any case the 
decrease in renal function disappears always completely after 
discontinuance of diazoxide (Thien et al, unpublished observations). 
The hyperglycemic effects of thiazide-denvatives are most 
pronounced with diazoxide. The drug inhibits the release of in-
sulin, whereas it causes at the same time glycogenolysis via an 
increase of the secretion of catecholamines (19,23). Indeed dia-
zoxide is even used for the treatment of hypoglycemia. 
Compensatory to the vasodilation and the decrease of the peri-
pheral resistance, the cardiac output increases via sympathetic 
stimulation, which may induce palpitations and a throbbing head-
ache. These complaints are seldom observed after a single intra-
venous administration and can be easily treated with ß-blockers. 
Other side-effects, such as sodium retention and hypertrichosis 
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appear after prolonged use only. When repeated injections have 
remained unsuccessful, administration of furosemide may be con-
sidered, since it is possible that the antihypertensive action of 
diazoxide is completely or partly antagonized by an increased 
extracellular volume caused by an already existing overhydration 
(6). 
Our experiences with the vasodilator drug diazoxide for the 
treatment of hypertensive crisis are very satisfactory. The side-
effects are minimal when the indications are selected carefully. 
Repeated injections are also well tolerated. If necessary, diure-
tics or 3-blockers can be added. Drugs to treat occasionally 
occurring hypotension must be at hand. Because the lowest blood 
pressure values are nearly always reached within 15 m m , careful 
monitoring beyond this period, which for reasons of security might 
be extended to 30 min, is not required. 
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Diazoxide infusion in severe hypertension and 
hypertensive crisis 
Prompted b\ report·, of hipotensión with nnoiautial isihemia after bolus injection we restudied 
the efßctii\ of diazoxide infusion (5 mg/kg. rate /5 mg/nun) in 35 h\perlensi\e patients In 20 
patients with (hronu Inpenension mean arte/tal pressure of 138 mm Hg was 110 (after 
30 mm) and 121 (aftei 8 hr) In 15 patients with Inpertensni' cusís, there was a fall from 159 
to 126 (in 30 mm) and ИЗ mm Hg (after 8 hr), similar to findings m 12 patients with 
Inpenensne aisis treated with a 300-mg bolus injection (159, /30, 140 mm Hg) In the latter, 
the maximal systolic blood pressure decrease was greater (56 mm Hg, reached m 4 mm) than m 
the 15 patients with Inpertensne crisis treated b\ slow infusion (38 mm Hg in 28 mm) Thus 
infusion of diazoxide causes a gradual decline of blood pressure and is, in contiast to current 
opinion, also an effecme treatment in Inpertensne crisis 
Theo A. Thien, M.D., Frans T. M. Huysmans, M.D., Paul G. G. Gerlag, M.D., 
Robert A. P. Koene, M.D., and Paul G. Α. Β. Wijdeveld, M.D..\'iim<geii The Netheilands 
Department of Internal Medicine, Dnision of Nephrologs, St Radboud Ziekenhuis, 
Uim ersitz of Nijmegen 
Diazoxide (Hyperstat) a nondiuretic benzo-
thiadiazine, has an immediate antihypertensive 
effect when administered intravenously to pa­
tients with hypertensive crisis There is contro­
versy on the optimal mode of administration 
Initially rapid administcration of the drug was 
recommended· 1 - 5 (within 30 sec or, better, 
within 10 sec16) because slow injection would 
not lower blood pressure effectively This was 
explained by the finding that 82% to 94% of the 
drug forms a supposedly inactive complex with 
albumin u 1 3 Only by very rapid administration 
would a sufficient amount of free drug reach its 
receptors to induce vasodilation 
Received for publication Oct 31, 1978 
Accepted for publication Jan 15 1979 
Reprint requests to Dr Theo A Thien Department of Internal 
Medicine, Division of Nephrology, St Radboud Ziekenhuis Uni-
vereity of Nijmegen Geert Grooteplein Zuid 16 Nijmegen The 
Netherlands 
This view was challenged by Crout et al,1 
who found that infusion was as effective as 
rapid injection Mroczek et al1 2 argued that the 
type of hypertension was important They re­
ported thai in hypertensive crisis (accelerated 
hypertension) infusion of diazoxide was inef­
fective, while patients with chronic hyperten­
sion responded equally well to rapid and slow 
administration The efficacy of infusion of 
diazoxide in patients with moderate hyperten­
sion was confirmed in two other studies β " It 
was concluded that in hypertensive crisis the 
generalized state of vasoconstriction was the 
reason more unbound diazoxide was required to 
lower the blood pressure 
Serious complications have been desenbed 
after rapid diazoxide injections,7, 1 0 , 7 which 
were most likely a consequence of decreased 
perfusion of vital organs as a result of the sud-
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Table I. Clinical dala in the patient gtoups 
Number ot patienls 
MAP (mm Hg ± SD) 
Age (yr) (mean + SD) 
Sex (nule/female) 
Left venlriLular h>peitroph>* 
Fundus III IVt 
Hvpertensive encephalopathy 
bndogenous ereatinine clearance 
Ml/min (mean ± SD) 
Civ 
lnfu\ioii (20 
они Іпреііеішоп 
(ι>ι<ηφ \) 
20 
118 ± 12 
41 ± 14 
8/12 
12 
1 
0 
76 ± 47 
to U) пни) 
H\peitensi\e Í /MÍS 
f Hi οιιρ ¡i) 
15 
159 ± 16 
40 ± 11 
8/7 
12 
12 
1 
47 ± 15 
Bolus 111ji(.IIOII 
Inpiitensne (nus 
(цюнр C) 
12 
159 ι 15 
18 ± 11 
6/6 
8 
9 
1 
10 ± 28 
*tlcctrocjrdioiírjphii entena according to Lstes i 
tAcLOrdmg (o Keith Wjgener and Barker s 
Table II. bffett of intraxenous diazoxule on blood pressiti e (mm Ηι>)* 
Gump A 
(n = 20) 
Gioup В 
In - 15) 
Gioup С 
(n = 12) 
Control 
Lowest 
10 mm 
60 mm 
8 hr 
value within 10 mm 
182/116 
(118) 
145/84 
(104) 
149/90 
(110) 
150/91 
(112) 
162/101 
(121) 
± 2V9 
(12) 
- 22/10 
( I D 
± 21/11 
(12) 
+ 21/11 
(14) 
i 27/16 
(19) 
205/116 
(159) 
167/97 
(120) 
174/102 
(126) 
177/107 
( 110) 
172/114 
(HI) 
25/16 
(16) 
19/20 
(17) 
24/19 
(18) 
27/19 
(19) 
10/21 
(21) 
214/112 
(159) 
158/97 
(117) 
179/106 
(110) 
178/109 
(112) 
181/118 
( 140) 
28/11 
(15) 
10/19 
(21) 
24/12 
(14) 
28/11 
06) 
14/19 
(21) 
*Mean ± SD are given Mean ancnal pressures -·- SD are gi\cn in parentheses For définition oí groups see Table 
den and large fall in blood pressure We have 
re-examined this problem and now present evi-
dence for the efficacy of diazoxide infusions in 
patients with nonmalignant chronic hyperten-
sion and in a group of patients with hyperten-
sive crisis 
Patients and methods 
Table I summanzes the clinical data in the 
patient groups Group A consisted ot 20 pa-
tients with chronic nonmalignant hypertension 
In this group, 11 patients had essential hy-
pertension, 5 renovascular hypertension, and 4 
hypertension with renal parenchymatous dis-
ease Seven of the 20 patients were on treatment 
(/3-blockade, diuretics) when they received the 
diazoxide infusion, the other 13 patients were 
without antihypertensive treatment Group В 
consisted of 15 patients with hypertensive 
crisis, as defined by Kaplan H In this group, 6 
patients had essential, 3 renovascular, and 6 
renal parenchymatous hypertension Five pa­
tients were never treated betöre, while the re-
maining patients used several combinations of 1 
to 4 (mean, 2 5) antihypertensive drugs Group 
С consisted ot 12 patients with hypertensive 
crisis, who received a rapid injection ot di­
azoxide In this group, 4 patients had essential, 
I renovascular, and 7 renal parenchymatous 
hypertension Five patients were untreated, the 
others used 2 to 4 (mean, 3) antihypertensive 
drugs Six patients in group В and 4 patients in 
group С were on diuretic therapy Patients of 
groups В and С can be considered unselected 
Until May, 1975, we always used the rapid in­
jection (group C) and thereafter always an infu­
sion (group B) 
The patients were in a supine position in a 
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Fig. 1. Effect ot dia/oxidc in hypertensne cnsis Companson of bolus (left) and infusion (right) 
For the sake of clarity, time to reach maximal blood pressure decrease is depicted as the mean ot the 
whole group This time was thus 4 mm (range, 2 to 6) after bolus and 28 mm (range, 22 to 34) alter 
the start ol the infusion 
quiet room during the study Blood pressures 
were measured at 2-min intervals with the Ar-
tenosonde 1217 and recorded by the Arteno-
corder 1509 (Roche). Before the administration 
of diazoxide, blood was drawn tor determina­
tion of total serum protein After recording 
of blood pressure during 30 mm, diazoxide 
(15 mg/ml) was infused at a rate of 15 mg/mm 
with an infusion pump (Braun, type 1850) The 
total amount administered was 5 mg/kg body 
weight Thus, the infusion time ranged from 20 
to 30 mm The rapid injections of dia/oxide 
(300 mg) were given by hand within 10 sec 
The prctreatment blood pressure was calcu­
lated as the mean of the last 5 measurements 
recorded before starting diazoxide infusion In 
two patients of group В and in two of group C, 
the systolic blood pressure was too high for ac­
curate measurement by the Artenosonde (above 
240 mm Hg) The level of 240 mm Hg was then 
taken as the pretreatment systolic pressure. The 
lowest blood pressure reading within 30 mm of 
the start of diazoxide was taken as the maximal 
hypotensive effect Means of at least 3 readings 
at 30 and 60 mm of the start of diazoxide admin­
istration (stable hypotensive effect) and at 8 hr 
(long-term hypotensive effect) were calculated 
Mean arterial pressure (MAP) was defined as 
the sum of the diastolic pressure and one third 
of the pulse pressure Student's t test was used 
for statistical analysis Ρ values of <0.05 were 
considered to be significant 
Results 
Table II gives the mean initial blood pres­
sures of all groups and the values after di­
azoxide In group A the mean maximal decrease 
in MAP was 34 mm Hg. At 30 mm, 60 mm, 
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and 8 hr, the mean MAP decreases were 28, 26, 
and 17 mm Hg and tor group В the decreases 
were 39, 33, 29 and 26 mm Hg, respectively 
The initial blood pressure in group В was sig 
nihcantly higher, but there were no significant 
ditlerences between the decreases in MAP In 
group C, MAP decreases were 42. 29, 27, and 
19 mm Hg The differences in MAP decreases 
between group В and group С were not sig­
nificant As expected, there was an important 
difference in the mean time in which the maxi 
mal blood pressure drop was obtained For 
group A this time was 26 and for group B, 28 
mm, while it was 4 mm for group С 
Fig 1 illustrates this relevant difference be­
tween the two procedures, showing a sudden 
and sometimes exaggerated fall especially in 
systolic blood pressure, in patients of group С 
(left panel) and the more gradual decrease in 
patients of group В (right panel) The mean 
maximal decrease in systolic blood pressure in 
group С was 56 ± 19 mm Hg and in group B, 
38 ± 18 mm Hg (p < 0 01) This difference 
had disappeared at 30 mm when systolic blood 
pressure decrease was 35 ± 21 mm Hg in 
group С and 31 ± 16 mm Hg in group В 
Because of the suggested importance of pro­
tein binding of diazoxide, total serum protein 
was measured The values were 70 8 ± 5 6 
gm// for group A, 68 7 ± 6 5 gm// for group 
B, and 69 4 ± 9 2 gm// for group С There 
were no significant differences 
There was no correlation between the creati­
nine clearance and the response to diazoxide 
Six patients with near normal renal function 
showed an equally good mean response (MAP 
decrease at 60 mm, 22 ± 4%) as the remaining 
patients of group В (MAP decrease, 16 ± 79c) 
In group A, all patients responded to the infu­
sion There were 2 nonresponders in group B, 
and 1 m group С Nonresponsiveness was de­
fined as a fall in MAP less than 10% at 60 mm 
One of the nonresponsive patients in group В 
had a good initial response (MAP decrease, 24 
mm Hg), but it was of short duration (60 mm) 
He was thereafter successfully treated with oral 
diazoxide and /3-blockade The other non-
responsive patient in this group was a woman 
with scleroderma She was also nonresponsive 
to 3 subsequent bolus injections Thereafter, 
she had a satisfactory blood pressure decrease 
after infusion of sodium nitroprusside There 
were no untoward side effects during and after 
diazoxide infusions 
Discussion 
Our results demonstrate that the administra 
lion of dia/oxide by infusion during 20 to 30 
mm is very effective m reducing high blood 
pressure both in chronic hypertension and in 
hypertensive crisis In the latter, the effect was 
similar to that of a group in which diazoxide 
was given by rapid injection The long-term 
hypotensive effect after infusion and rapid in­
jection was also the same and was maintained 
during at least 8 hr 
We have no explanation for the difference 
between our results and those of Mroczek et 
al,12 who reported no effect for a 10-min infu­
sion with similar doses of dia/oxide in patients 
with accelerated hypertension A difference 
with our study was that Mroc/ek's patients all 
were black On the other hand, all of his pa­
tients had essential hypertension, and the re­
sponse of the 6 patients with essential hy­
pertension in our group В was even slightly bet­
ter than the response in the rest of the patients in 
this group The effectiveness of diazoxide infu­
sion in our patients was not caused by lower 
serum protein levels, since these levels were 
normal in all three groups studied 
It has been shown that binding of diazoxide 
to protein is less in uremia,11 l 4 and this might 
explain why infusion was effective in group В 
(Table I) However, the 6 patients in group В 
with near normal renal function also had excel­
lent responses Mroc/ek et al'2 did not mention 
renal function in their patients It might be ar­
gued that most of our patients in groups В and С 
were on multiple antihypertensive therapy, 
while in the study of Mroc/ek12 all treatment 
was discontinued 7 days before the administra­
tion of diazoxide The 5 previously untreated 
patients in our group В had as good responses 
(MAP decrease, 18 ± 10%) as the 10 patients 
who were on treatment (MAP decrease, 18 ± 
6%) This makes it unlikely that concomitant 
antihypertensive therapy influenced our results 
The more gradual decline of blood pressure 
during the infusion stands in contrast to the sud-
den and somet imes exaggerated response to 
rapid administrat ion Infusion, therefore, low­
ers the risk of myocardial i schemia, such as has 
been reported after the latter p r o c e d u r e . 7 ' " ) · l 7 
Others"* have reported that multiple small in­
ject ions are also effective and are preferable to a 
single bolus. The infusion is. however , more 
attractive because of its simplicity and safety. 
T h e technique makes it possible to interrupt the 
procedure as soon as a satisfactory blood pres­
sure level is reached or when untoward side 
effects b e c o m e evident . Like the injection, the 
slow infusion can be repeated if necessary. 
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SUMMARY 
Eight patients with severe pre-eclampsia or eclampsia were 
treated with diazoxide. The drug was administered at three occa-
sions as a bolus injection (300 mg within ten seconds) and at 
eight occasions as an infusion (15 mg/min, total amount 5 mg/kg 
body weight). The hypotensive effect at 30 and 60 minutes (stable 
hypotensive effect) and at 7 hours (long-term effect) were the 
same with both modes of administration. The maximal decrease in 
blood pressure was reached in five minutes after bolus injection 
compared to 25 minutes with the infusion. If diazoxide is used 
in severe pre-eclampsia and eclampsia, it should be administered 
preferably by the infusion method, because this results in a more 
gradual decline of blood pressure. Furthermore, the administration 
can be easily interrupted in case of an exaggerated fall of blood 
pressure. 
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INTRODUCTION 
Uteroplacental ischaemia and consequent generalized vasocon-
striction play an important role in the etiology of pre-eclampsia 
and eclampsia (Ferris,197S). Cerebral haemorrhages are the most 
frequent cause of maternal death in eclampsia (Chesley,1978). 
Therefore, when there are signs of encephalopathy, immediate 
treatment is mandatory. Measures to save the foetus are of secon-
dary concern under these conditions. 
The most attractive approach to treatment is lowering of the 
peripheral resistance with vasodilator drugs. Theoretically, this 
would decrease the blood pressure without jeopardizing organ per-
fusion. Diazoxide, a non-diuretic benzothiadiazine is a strong 
antihypertensive agent and its effect is caused by a direct 
relaxation of vascular smooth muscles in the pre-capillary resis-
tance vessels. Finnerty (1970) found that the drug was very effec-
tive in pre-eclampsia and eclampsia and this has been confirmed 
by others (Michael, 1973; Morris et al, 1977). It has been re-
commended to administer diazoxide by a rapid (10 to 15 seconds), 
so-called bolus injection, otherwise it would be ineffective 
(Mroczek et al, 1971). This was attributed to the high percentage 
of protein binding of the drug (Sellers and Koch-Weser, 1969). 
An obvious disadvantage of the bolus injection technique is the 
sudden and large fall in blood pressure that follows. A more 
gradual decline seems preferable. In a study of non-pregnant 
patients with a hypertensive crisis we found that slow (20 to 30 
minutes) infusion of diazoxide was as effective as a rapid in-
jection (Thien et al, 1979). We have, therefore, studied whether 
this finding also holds for pre-eclampsia and eclampsia. In this 
report we describe the effects of bolus injection and slow in-
fusion in 8 patients with severe (pre-)eclampsia. The results are 
compared with those in two groups of non-pregnant patients with 
a hypertensive crisis who received diazoxide by bolus injection 
and slow infusion respectively. 
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PATIENTS AND METHODS 
Clinical data of the patients before diazoxide administration 
are given in Table I. They all had severe hypertension (mean 
197/132 mmHg), proteinuria and edema, and showed signs of ence-
phalopathy ranging from hyperreflexia, headache and epigastric 
pain to convulsions and coma. Table II gives the relevant labora-
tory data. All patients showed liver function disturbances and, 
in the majority, signs of intravascular coagulation were found. 
All patients were admitted to the obstetric ward and were treated 
with bed rest, diazepam (5-50 mg/hr) and diuretics or salt-poor 
diet. Because the hypertension was unreactive and, in most cases, 
encephalopathy aggravated, diazoxide was administered. Seven 
patients received the drug during pregnancy, while one patient 
was treated when, after termination of pregnancy by cesarean 
section, the symptoms did not ameliorate. Three patients received 
diazoxide twice, because the blood pressure rose and symptoms 
returned within 3-6 hours after the first administration. Patient 
2 was treated by both infusion and bolus iroection. The bolus 
injections were given by hand in less than 10 seconds. For the 
infusion, diazoxide (15 mg/ml) was administered at a rate of 15 
mg per minute with an infusion pump to a total amount of 5 mg/kg 
body weight. Thus the infusion time ranged from 20 to 30 minutes. 
Blood pressures were measured at two minute intervals with the 
Artenosonde 1217 (Roche, Medical Electronic Division, Orange-
burg, N.J., U.S.A.) on the right arm, while the patient was m 
the left lateral recumbent position. The pre-treatment blood 
pressure was calculated as the mean of at least 5 values recorded 
before the start of diazoxide treatment. The lowest reading 
within 30 minutes after diazoxide was taken as the maximal hypo-
tensive effect and the time m which this value was reached was 
noted. Means of at least 3 readings at 30 and 60 minutes (stable 
hypotensive effect) and at 6-7 hours (long-term hypotensive 
effect) were calculated. In the non-pregnant hypertensive groups, 
consisting of 12 patients treated with a bolus injection and 15 
patients treated with a slow infusion, the protocols for ad-
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TABLE I. Clinical data 
Patient Pregnancy Parity Äge Amenorrhoea Blood pressure Proteinuria Grand mal Mode of Clinical 
number (yrs) (weeks) (mmHg) g/24 h) seizures delivery diagnosis 
22 29 190/140 5.0 vaginal pre-eclampsia 
27 
30 
35 
26 
27 
1 32 
34 
36 
24 
34 
30 
30 
23 
29 
190/125 
165/120 
200/140 
250/140 
200/140 
200/115 
180/134 
0.4 
23.0 
1.7 
7.5 
1.0 
6.9 
0.9 
no cesarean pre-eclampsia 
yes vaginal eclampsia 
yes cesarean eclampsia 
yes vaginal eclampsia 
yes cesarean eclampsia 
no vaginal pre-eclampsia 
no cesarean pre-eclampsia 
Mean of two casual readings 
This case is described in a separate report (van Dongen et al, 1979) 
TABLE II. Laboj'at-opy aata 
Patient Mode of diazoxide Creatinine U n e acid 
administration (μΜ/l) (mM/1) 
bolus 
infusion 
bolus 
infusion 
infusion 
infusion 
bolus 
infusion 
infusion 
infusion 
infusion 
normal values 
147 
83 
156 
124 
71 
89 
Liver functions 
SGOT SGPT LDH 
U/l U/l U/l 
Intravascular 
coagulation* 
0.69 
0.55 
0.63 
0.75 
0.50 
0.52 
59 
96 
< 75 
0 .30 
0 . 5 4 
0 . 2 0 - 0 . 4 0 
131 100 1630 
235 343 690 
85 40 490 
29 26 395 
12 16 260 
420 368 2200 
2000 2100 11,520 
114 252 772 
< 15 < 15 <175 
thrombocytopenia and/or low fibrinogen and/or increased fibrinogen degradation products. 
oo 
ministration and evaluation were the same. The results in these 
patients have been reported in detail (Thien et al, 1979) and are 
used here for reasons of comparison. Mean arterial pressure (MAP) 
was calculated as the sum of the diastolic pressure and one-third 
of the pulse pressure. 
Statistical methods used were Student's t-tests for paired and 
unpaired observations. 
RESULTS 
Diazoxide administration induced a satisfactory decrease of 
blood pressure in all patients. Figure 1 shows the individual 
maximal and stable hypotensive effects. After the bolus injection 
0 5 3 0 60 о 5 
t ime (mmJ • 
30 6 0 
systolic 
blood -ι bolus in ject ion slow infus on 
Fig. 1. Effect of a bolus injection of diazoxide in three patients (left panel) 
and of eight infusions of diazoxide in six patients (right panel) with 
severe pre-eclampsia or eclampsia. 
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there was a precipitous fall in blood pressure that was maximal 
at 5 minutes (mean MAP decrease, 43%). With the infusion, blood 
pressure decreased more gradually. The maximal mean MAP decrease 
was 33% and this value was reached in 28 minutes. The figure 
also illustrates that especially the systolic pressures showed 
an exaggerated fall after the bolus injection. In two of the 
patients this value fell below 100 mmHg, while this was not the 
case m any of the patients m the infusion group. After a bolus 
of diazoxide the mean decrease of MAP was 30% after 30 minutes 
and 28% after 60 minutes. For the group who received an infusion 
these values were 29 and 26%. Thus, the stable hypotensive effect 
was the same with both procedures. Figure 2 compares the effects 
m the pregnant patients with those in non-pregnant patients with 
a hypertensive crisis. The mean starting blood pressures are low­
er in the pregnant group whereas the reaction tends to be stronger. 
0 5 
ι u 
mm h 
60 6-8 0 5 
120-
Θ0-
blood bolus injection 
pressure -. τ 
mmHg 9 
200 
160 
Fig. 2. Treatment of severe hypertension in pregnant patients with diazoxide 
as a bolus injection (Left) or as a slow infusion (right) (solid lines) 
Results in similarly treated non-pregnant hypertensive crisis (bolus 
injection: 12 patients and slow infusion: 15 patients) are given for 
comparison (broken lines). Means + SbM are given. 
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This latter effect might be related to the significantly lower 
serum protein levels m pregnant as compared to non-pregnant pa­
tients (59.1 + 5.8 vs. 69.9 + 7.8 g/1, ρ «- 0.001) with consequent­
ly higher levels of free diazoxide in the circulation. Patient 2 
received both an infusion and a bolus infection with a MAP de­
crease of 18% and 20% respectively. In the whole group of patients 
there was a reversible increase in the serum creatinine level 
from a mean of 103 + 35 to maximal 152 + 57 μΜ/1 after diazoxide. 
Hyperglycemia, a well-known side-effect of diazoxide, posed no 
problem. Mean blood glucose increased from 4.8 + 0.7 to 7.9 + 4.4 
mM/1 with a value above 10 mM/1 m only one patient. In Table III 
the other relevant data of the pregnancies are given. As antici­
pated, perinatal mortality was high in this group. In two patients 
fetal heart sounds were already negative before diazoxide admi­
nistration. In two others the foetus died in utero four and seven 
days after diazoxide. Three patients gave birth to live children, 
of whom two died later. Patient 2 had a cesarean section with a 
live child before she received diazoxide. 
DISCUSSION 
Treatment of severe hypertension during pregnancy with the 
strong vasodilator diazoxide seems an attractive approach since 
vasoconstriction is an important etiologic factor in pre-eclamp-
sia and eclampsia (Ferris, 1975; Chesley, 1978). There are indeed 
experimental data showing that diazoxide does not decrease utero­
placental blood flow despite great reduction in blood pressure 
(Venuto et al, 1976). On the other hand. Brinkman and Assali 
(1976) found a decrease in uteroplacental blood flow in hyper­
tensive sheep and this was only seen during the first 30 minutes 
after a bolus injection of diazoxide and coincided with an exag­
gerated and precipitous fall in blood pressure. In the clinical 
situation bolus injection of diazoxide also results in a sudden 
and large fall in blood pressure. Our results demonstrate that 
the fall in blood pressure after bolus injection is even more 
exaggerated in pregnant than in non-pregnant patients. This might 
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TABLE in. Results of pregnancies after treatment with diazoxide 
Pregnancy data Patient Amenorrhoea 
at birth sex birth percentile'* fetal outcome 
(weeks) weight (g) 
Time interval between 
placental diazoxide adminxstra-
weight (g) tion and death (days) 
1 
2 
3 
30 
36 
24 
F 
M 
F 
960 
2010 
440 
5-10 
5-10 
2.3-5 
4 
5 
6 
7 
34 
32 
30 
23 
M 
M 
F 
F 
1500 
1400 
960 
490 
2.3-5 
10-25 
5-10 
25-50 
31 M ИЗО 5-10 
intrauterine death 
alive** 
intrauterine death 
before diazoxide 
death day 4 I.H.D.S. 
intrauterine death 
alive 
intrauterine death 
before diazoxide 
death day 4 I.K.D.S. 
150 
410 
95 
360 
00 
190 
130 
295 18 
According to Kloosterman (1977) 
Delivery before treatment with diazoxide 
Idiopathic respiratory distress syndrome 
ш 
be caused partly by the lower protein levels in the former group, 
which can lead to a higher concentration of free diazoxide 
(Sellers and Koch-Weser, 1969). Other differences between the 
pregnant and non-pregnant patients were: a lower age, a lower 
pre-treatment blood pressure, a better renal function, salt deple-
tion by diet or diuretics, and a shorter duration of the hyperten-
sive disease in the pregnant group. All these factors could have 
contributed to the greater sensitivity to diazoxide in the preg-
nant group. Therefore an equally effective treatment with a more 
gradual decline in blood pressure seems preferable, especially 
in severe hypertension during pregnancy. We have earlier shown 
that, in contrast to literature reports (Mroczek et al, 1971) 
this can be achieved in non-pregnant patients by slow infusion of 
diazoxide (Thien et al, 1979) and the results presented in this 
paper demonstrate that this also holds for pregnant patients. The 
rate of infusion was arbitrarily chosen as 15 mg/minute but pos-
sibly slower infusion rates can be equally effective. We have 
recently seen two pregnant patients, who reacted to 7.5 mg/minute 
with a satisfactory decrease in blood pressure. Another advantage 
of the slow infusion is that the treatment can be interrupted if 
the antihypertensive effect is sufficient. 
Although the results of our study make it unlikely, that the 
perinatal mortality was caused by diazoxide, the data are on the 
other hand not sufficient to warrant the conclusion that diazoxide 
is harmless to a live fetus. It has been shown in animal experi-
ments that the drug crosses the placental barrier and may cause 
necrosis of the fetal pancreas (Boulos et al, 1971). However, the 
doses used in this study were several times higher than those used 
in the clinical situation. These side-effects were not seen after 
intravenous administration in several large clinical series 
(Finnerty, 1970; Michael, 1973; Morris et al, 1977). Moreover, 
there are reports of prolonged use of diazoxide in human pregnancy 
without manifest damage to the newborn, except for hypertricho-
sis (Milner and Chouksey, 1972). 
When diazoxide is used to treat severe pre-eclampsia and eclampsia, 
the slow infusion technique will be the method of choice. The 
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hypotensive effect of diazoxide remains during 6-7 hours. This 
is long enough to give the opportunity for operative termination 
of pregnancy. Alternatively, the infusion can be repeated and is 
then still effective as we could show in two patients. 
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Treatment of severe hypertension with oral diazoxide and β-adrenergic 
blockade 
TH. THIEN, R. A. P. KOENh and P. G. A. B. 
SUMMARY 
Seventy-four patients with severe and often 
drug-resistant hypertension (mean diastolic 
pressure 134 mm Hg) were treated by oral ad­
ministration of the vasodilator agent diazoxide 
(100-500 mg daily), in combination with a β-
sympathicolytic drug. The hypotensive effect 
was evaluated in 49 patients, who had been 
treated for more than 3 months. The mean de­
crease in systolic blood pressure was 56 mm Hg 
(27 per cent). Mean diastolic blood pressure fell 
by 41 mm Hg (30 per cent). Postural hypoten­
sion did not occur. The side effects, evaluated in 
all 74 patients, were the following: hyper-
glycaemia (38 per cent), hypertrichosis (35 per 
cent), nausea (23 per cent), palpitations (11 per 
cent), exanthema (2.7 per cent). Sodium reten­
tion occurred in nearly all patients, but was 
controlled with diuretics. The hyperglycaemia 
responded in all cases to treatment with tol­
butamide. The incidence of hypertrichosis was 
higher than that reported in the literature. Side 
effects led to withdrawal of diazoxide in 12 pa­
tients (17 per cent). In the other 62 patients the 
side effects were slight or easily controlled. In 
nearly all patients there was an initial increase in 
serum creatinine, which accompanied the de­
crease in blood pressure. Thereafter, renal 
function remained stable or improved slightly in 
the majority of patients. The combined use of 
diazoxide and a/3-sympathicolytic drug is a good 
approach to the treatment of so-called drug-re­
sistant hypertension. Neth. J. Med. 21, 11. 
INTRODUCTION 
The use of vasodilator agents in combination 
with ^-adrenergic blockade has proved to be of 
Department of Medicine, Division of Nephrology, St Radi 
great value in the treatment of hypertensive pa­
tients. Effective control of the blood pressure 
can often be achieved by the use of hydralazine 
together with a ^-blocking drug (e.g. pro­
pranolol) and a diuretic agent (e.g. chlorthali­
done) 1 4. But there remains a group of patients 
that is refractory to this form of treatment. Most 
of these patients are severely hypertensive with 
diastolic blood pressures above 120- 130 mm Hg. 
Especially in patients with nephrogenic hyper­
tension the response to this regimen is often 
disappointing. The adrenergic neuron-blocking 
and ganglion-blocking agents are no good alter­
native, since treatment with these drugs in ade­
quate doses always results in postural hypoten­
sion while renal function may seriously dete­
riorate. 
The use of more potent vasodilator agents 
such as diazoxide (7-chloro-3-methyl-2N-
i,2,4-benzothiadiazine-i,i-dioxide) seems to 
offer a better approach to treatment in these 
cases. Despite its strong vasodilator action, 
diazoxide has not been used on an extensive 
basis because the compensatory increase in car­
diac output leads not only to palpitations and 
headache, but probably also to a decrease in 
hypotensive effectivity4. The drug also induces 
sodium retention and hyperglycaemia. More­
over, it was erroneously thought that it was only 
effective after fast intravenous injection. The 
oral use of diazoxide was advocated by POHL and 
THURSTON7, who reported that treatment with 
this drug controlled severe hypertension and 
resulted in improvement of renal function even 
in patients with severe renal insufficiency. Es­
pecially the latter finding prompted us to study 
the effects of diazoxide in patients with decreas­
ed renal function. Since 1973 we have treated 
d Hospital, University of Nijmegen. 
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74 patients with a combination of diazoxide and 
propranolol In this paper we report on the ef­
fective control of blood pressure by this com­
bined treatment Particular attention is payed to 
the influence of dia7oxide on renal function and 
to its untoward side effects. 
PATIENTS AND MFTHODS 
The causes of the hypertension in the 74 patients 
(26 females, 48 males, mean age 39 years) 
treated with diazoxide are given in Table I. In 66 
patients previous intensive treatment with se­
veral antihypertensive drugs (mean 4 6 
drugs/patient) had been insufficient All drugs 
were discontinued except propranolol, which 
was administered in a dose of 240 mg daily. To 
this treatment 100 mg diazoxide daily was ad­
ded, and this dose was gradually increased until 
effective control of diastolic pressure (<90 mm 
Hg) was achieved or, alternatively, a dose of 300 
mg daily was reached Diuretics were added as 
soon as there were signs of sodium retention. 
mostly within the first week of treatment. In the 
8 patients previously untreated and admitted to 
hospital with malignant hypertension, blood 
pressure was first lowered with diazoxide intra­
venously and treatment was then continued with 
propranolol and oral diazoxide without a trial of 
other therapeutic regimens. Most of the other 
patients were not hospitalized when the 
TABIt I CAUSES OF HVPERIFNSION IN 74 PATIENTS 
Diagnosis Number % \11mber with 
of malignant 
patients Inpertinsion 
Parent h\mal renal disease 
Glomerulonephr i t i s iK 24 4 
Pyelonephritis 10 14 2 
PolycNstic kidne\s 4 s 
Analgesic nephropathv 2 4 
Graft rejection 2 ч 
Reiun oscular disease 
Renal artery stenosis 
Renal artery stenosis in 
kidney graft 
Essential hypertension 
11 
1 
24 
IS 
4 
42 
S 
16 
treatment was started, but they were seen 
weekly, later at 2-4 weekly intervals in the out­
patient clinic To ascertain that a new steady 
state was reached the antihypertensive effect 
was evaluated only in patients who had used 
diazoxide for at least 3 months. Blood pressure 
was measured after at least 5 minutes of recum­
bency and immediately after standing Phase V 
of the Korotkoff sounds, measured with a le­
gally stamped sphygmomanometer (Erkameter 
300), was determined as the diastolic pressure 
Mean arterial pressure (MAP) was defined as 
the sum of diastolic pressure and one-third oi 
pulse pressure Blood pressure was determined 
as the mean of the readings at 3 consecutive 
visits before diazoxide was started. The effect ot 
treatment was measured by taking the mean ol 
the blood pressure readings at 3 consecutive 
visits after a constant dose ot diazoxide had been 
reached 
Side effects were evaluated in all 74 patients 
Patients were weighed at each visit, the presence 
of oedema and hypertrichosis was recorded, and 
they were asked for complaints Venous blood 
was drawn for measurement of creatinine and 
glucose. Patients were instructed to test then 
urine for the presence of glucose at regular in­
tervals with Glukotcst* (Bochrmger, Mann­
heim) As soon as glucosuria occurred they were 
seen in the out-patient clinic and, if hyper-
glycaemia was found, treatment with tolbuta 
mide was instituted 
RESULTS 
A ntihyperten чі е effects — In 25 of the 74 patients 
the antihypertensive effect was not evaluated 
because they had used the drug for less than 3 
months In 16 of these patients therapy was dis­
continued because of side effects or because 
treatment was no longer indicated (haemo-
dialysis, renovascular surgery) The remaining 9 
patients were still on the drug at completion ol 
the study, but had been less than 3 months 
Table II shows the results of treatment in the 4t, 
patients, with a mean follow-up of 9 month 
(range 3-27). Mean blood pressure decreased 
supine from 208/135 to 152/93 mm Hg and stand 
oral (lta;o\iíle in Ихрепеішон 
lAHIf II III ООП PRI-SSl'RI BbbORh AND DURINO TRI ATMFNT WITH ORAI ПІЛ/ОХШЬ IN 4 4 PAT1I-NIS 
Before t rea tment 
During t reatment 
Decrease (mm Hg) 
Decrease ("i.) 
" m e a n ± S D 
s\ stola 
208 ± 32 
1 «52 t 18 
56 
27 
supim' 
diastolic 
134 + 15 
93 ± « 
41 
3 ' 
Hhod pressure' 
s\ stolti 
190 ± 20 
148 ± 24 
42 
22 
standing 
diastolic 
'3<> ± 'S 
95 ± Π 
35 
27 
ing from 190/130 to 148/95 mm Hg. The Table 
also shows that there was no orthostatic hypo­
tension during this regimen. The slight or­
thostatic hypotension present before diazoxidc 
was started, was due to other medication, e.g. 
guanethidine, Clonidine and a-methyldopa. 
Effects on renal function - Regardless of the 
underlying cause of their hypertension, nearly 
all patients showed an increase in serum creati­
nine level within the first few weeks of treatment 
(Fig. 1 ). In 3 patients renal function could not be 
evaluated because they were on haemodialysis 
while taking diazoxide. The figure shows that, 
after the first week, renal function remained 
creatinine (mg/100ml ) 
2 0 -
2S¿ 
У 
о ^ 
parenchymatous 
renal disease 
renovascular 
disease 
essential 
hypertension 
Fig. 1. Influence of diazoxidc treatment on renal function in 
46 patients. In each group the scrum creatinine level is given 
before, after 4 weeks, and after at least 12 weeks of 
treatment. 
stable or improved slightly in most patients. The 
pre-diazoxide level, however, was reached in 
only locases. In 1 patient with glomerulonephri­
tis there was a rapid decline of renal function 
but this was probably related to the activity of 
the disease and not a consequence of the antihy­
pertensive therapy. In 14 patients who used 
diazoxide for more than 12 months there was no 
significant further improvement of renal func­
tion (Fig. 2A). Fig. 2B shows that renal function 
returned to its pre-treatment level in 14 other 
patients in whom diazoxide had to be discon­
tinued. 
Side effects — The side effects and their fre­
quencies in all 74 patients are summarized in 
Table III. In 12 patients the side effects were the 
only reason for discontinuation of treatment 
(glucosuria 1, hypertrichosis 5, palpitations and 
nausea 4, allergic exanthema 2). There was an 
creatinine (mg/100 m ) 
10 
80 
60 
10 
08 
06 
creatinine (mg/100 ml ) 
10 
eo 
60 
40 
10 
0 
06 
before after after^ 12 months 
4 weeks before during alter 
Fig 2. Renal function after long-term use of diazoxide (A). 
Changes in renal function after discontinuation of 
diazoxide (B). 
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TABLI- III: SIDE EFFECTS OF ORAL DIAZOXIDE IN 7 4 PATIENTS 
Side effect Number 
of 
patients 
Oedema 44 
Hyperglycaemia (glucose > 180 mg/100 ml) 28 
Hypertrichosis 26 
Nausea, vomiting 17 
Palpitations 8 
Exanthema 2 
% 
59-5 
37·« 
3 5 ' 
23.0 
10.8 
2.7 
obvious increase in body weight (mean 3.6 kg; 
range 0-11.2 kg) due to sodium retention, which 
led to overt oedema in 44 patients. In all patients 
this was controlled with chlorthalidone (50-100 
mg daily) or with furosemide (20-500 mg daily, 
mean 140 mg). Large doses of furosemide (up to 
1000 mg daily) were required temporarily to 
treat the oedema in some patients with renal 
insufficiency. Only in exceptional cases was it 
necessary to combine diuretic treatment with 
dietary salt restriction. 
Hyperglycaemia, arbitrarily defined as a 
highest blood glucose of > 180 mg/100 ml, was 
seen in 28 patients. Hyperglycaemia occurred 
more frequently at larger doses of diazoxide. 
Seven out of the 35 patients (20 per cent) who 
used less than 200 mg daily showed hyper-
glycaemia, while of the remaining 39 patients, 
who were on more than 300 mg, 21 (54 per 
cent) had high blood glucose levels. This dif-
ference is significant (p <o.oo5). In the patients 
with severe hyperglycaemia (blood glucose 
>350 mg/100 ml) additional diabetogenic fac-
tors (chlorthalidone, prednisone, or raised 
blood sugar before treatment) were often pre-
sent. In all patients the hyperglycaemia res-
ponded to tolbutamide (500-1000 mg/24 hrs) 
and sometimes this treatment was needed only 
temporarily. In only 3 cases was insulin therapy 
used initially. 
Hypertrichosis occurred in 26 of 74 patients 
(35 per cent). The incidence was highest in wo-
men and was seen in 11 out of 12 women who 
were taking a daily dose of 300 mg diazoxide. It 
is likely, however, that the actual incidence in 
men is higher, because for obvious reasons slight 
hypertrichosis is usually not noted in this sex. 
When all patients who had used diazoxide for 
longer than 3 months were divided into 2 
groups according to age, it was found that the 
incidence of hypertrichosis was significantly 
higher in patients under age 40 (p <o.025). 
Pancreatitis, a complication reported in a pa-
tient who used diazoxide1, was not observed by 
us. Serum amylase levels remained normal in all 
patients. 
DISCUSSION 
Diazoxide lowers high arterial pressure by re-
laxation of the vascular smooth muscles, pos-
sibly by its action on calcium receptors12,13. It 
does not act via the sympathetic nerves, but has 
a direct effect on smooth muscle. Our study 
shows that a combined regimen of oral 
diazoxide and propranolol can effectively con-
trol severe hypertension, without occurrence of 
postural hypotension. If, arbitrarily, a 15% re-
duction in MAP is taken as an antihypertensive 
effect, there were only 3 non-responders in the 
group and 2 of these were real doubt whether 
they had taken their medication. It cannot be 
excluded that part of the antihypertensive effect 
was due to the action of /3-blockade and/or 
diuretics. However, we found that diazoxide 
was always required to achieve effective control 
of hypertension in our patients. Furthermore, 
with regard to the hypotensive effect of furose-
mide, it is worth mentioning that in many pa-
tients the maximum fall in blood pressure oc-
curred before treatment with furosemide was 
started, and the hypotensive effect often per-
sisted even in the presence of considerable 
oedema. Diazoxide reduced the systolic and the 
diastolic blood pressure to the same extent. Side 
effects such as palpitations and headache, which 
often occur when the drug is used alone, were 
almost completely prevented by the concomi-
tant use of /J-blockade. Patient acceptance of 
the therapeutic regimen was good because 
faintness and tiredness were absent and because 
the patients usually had to take fewer pills. In 
most patients drug adherence could be checked 
by the occurrence of side effects, e.g. hyper-
trichosis and sodium retention. POHL and 
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THURSTON7·9 reported that the great majority of 
their patients showed improvement of renal 
function during treatment with diazoxide. We 
did not observe such improvement after long-
term treatment. There was, on the contrary, a 
decrease in renal function in most patients as 
soon as the blood pressure fell. Thereafter the 
renal function remained stable at this level in 
most cases. We presume that the changes in 
renal function were related to the iluctuations in 
blood pressure. This is in accordance with a 
study of JOHNSON2, who found that a 
diazoxide-induced reduction in MAP of 18 per 
cent resulted in a 27% reduction of the inulin 
clearance in hypertensive patients. Another ar­
gument can be found in our observation that, in 
the 14 cases where diazoxide was stopped, the 
serum creatinine promptly returned to pre-
treatment levels (Fig. 2B). Nevertheless, since 
severe hypertension as such has a deleterious 
effect on renal function, it is possible that ef­
fective treatment with diazoxide prevented 
further deterioration of renal function. Our re­
sults show that diazoxide could be used in pa­
tients with severe renal disease and, therefore, 
we cannot support the contention of MUSSCHE ei 
al.5 that impaired renal function is a contrain­
dication to its use. 
The frequent occurrence of hyperglycaemia 
has limited the extensive use of diazoxide as an 
antihypertensive agent. We found, in ac­
cordance with POHL and THURSTON7, that in all 
patients hyperglycaemia could be controlled 
with tolbutamide. The hyperglycaemia always 
reverses spontaneously when treatment with 
diazoxide is discontinued. Our results suggest 
that one should be especially aware of hyper­
glycaemia when other diabetogenic agents such 
as prednisone or chlorthalidone are used con­
comitantly. 
Hypertrichosis is a very troublesome side ef­
fect and it often makes the use of diazoxide in 
women impossible. It is likely that the increased 
hair growth is a result of vasodilatation per se, 
for the vasodilator minoxidil (which is chemi­
cally unrelated to diazoxide) has a similar effect. 
Furthermore, no hormonal disturbances have 
been found in patients treated with diazoxide3. 
We have no explanation for the finding that the 
incidence is higher at younger age. It is im­
portant to know that the hypertrichosis always 
disappears after discontinuation of diazoxide, 
although this may take 2-5 months6. 
It has been suggested8-10 that diazoxide 
causes sodium retention by induction of hypo-
volaemia due to the vasodilatation, and not by a 
direct action on tubular sodium reabsorption. 
This, however, does not explain why the pa­
tients develop manifest oedema in most cases. It 
is tempting to speculate that the relaxation of 
precapillary arterioles without a concomitant 
change in postcapillary venular tone 1 1 causes a 
rise of the hydrostatic pressure in the capillary 
bed, which leads to extravasation of plasma 
water. This would then be the counterpart of the 
nephrotic oedema that is (he result of a decrease 
in oncotic pressure. 
We feel that the combined use of potent vaso­
dilators such as diazoxide and minoxidil in com­
bination with ^-adrenergic blockade has be­
come an indispensable tool in the treatment of 
patients with severe hypertension. Because of 
its serious side effects, diazoxide should only be 
used in patients who cannot be treated by other 
antihypertensive regimens. After long-term 
use, tolerance is excellent, especially because 
blood pressure is controlled without the oc­
currence of postural hypotension. 
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SUMMARY 
In ten hospitalized hypertensive patients the effects of addi-
tion of the ß-blocker propranolol (120-240 mg daily, during five 
days) to the vasodilator diazoxide (300 mg daily orally) were 
examined with respect to mean arterial pressure (MAP), heart rate 
(HR) and plasma renin activity (PRA). Diazoxide induced a decrease 
in MAP of -12.9%; addition of propranolol caused a further de-
crease of -24.4%. The total MAP decrease was -35.6%. The anti-
hypertensive effect of propranolol was completely expressed on 
the first day of its administration. HR increased during diazoxide 
with 20.1% and decreased during propranolol to -11% below the 
control value. PRA showed the same pattern with +84% and -23% 
respectively. All these changes were seen despite a continuous 
sodium retention and increase in body weight (mean + 2.4 kg). 
Plasma creatinine levels increased during both drugs and the in-
crease was significantly correlated with the percentual decrease 
in MAP (r = -0. 70) . 
We conclude that the hypotensive effect of the addition of 
propranolol to a vasodilator is much greater than the effect of 
propranolol, when used alone. This effect is explained by an ef-
fective inhibition of the sympathetic stimulation, that follows 
treatment with strong vasodilators. 
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INTRODUCTION 
An attractive way to treat hypertension is the use of directly-
acting vasodilators, because the increased peripheral vascular 
resistance is the most constantly found haemodynamic disturbance 
in established hypertension (4,6,10,14). Monotherapy with these 
drugs, however, is hardly possible, since in most patients palpi-
tations and edema develop as a consequence of the peripheral 
vasodilation (14). For this reason vasodilators are usually ad-
ministered in combination with 0-adrenoreceptor blocking drugs 
and diuretics. Therapeutic regimens of this sort are highly 
effective in the chronic treatment of hypertension (1,11,15,19, 
21). The compensatory reactions to single treatment with vaso-
dilators not only cause subjective complaints, but may also anta-
gonize the antihypertensive effect of the vasodilator (6,14). 
It is not clear to what extent this latter phenomenon occurs, 
since most patients use a combination of drugs right from the 
start of the treatment. This makes it also impossible to assess 
the contribution of each individual drug to the antihypertensive 
effect. 
In the present study we have found, in a standardized treat-
ment protocol, that the addition of a ß-blocker to diazoxide in-
duces an immediate and strong antihypertensive effect, which goes 
along with inhibition of the compensatory haemodynamic reactions 
to the vasodilator. Furthermore, measurements of the cumulative 
sodium balance suggest, that the antihypertensive effect of this 
regimen is hardly antagonized by the vasodilator-induced sodium 
retention. 
PATIENTS AND METHODS 
Ten hypertensive patients, in whom previous medication was 
discontinued for at least two weeks, were admitted to the hospi-
tal. All patients gave informed consent for the study. Table I 
lists the clinical data at admission. The patients werd put on a 
diet with fixed sodium (6 g of NaCl daily in eight patients and 
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TABLE I . ClinicaL data before start of the treatment 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Age 
(yrs) 
29 
21 
52 
47 
33 
39 
27 
35 
33 
55 
Sex 
M 
F 
M 
F 
M 
M 
M 
M 
M 
F 
Blood pressure 
(mmHg) 
195/140 
210/140 
240/140 
260/150 
226/148 
210/138 
210/150 
215/150 
162/120 
260/140 
ECC1 
(ml/min, 
25 
97 
88 
31 
24 
21 
16 
121 
46 
68 
LVH' Hypertensive 
retinopatny**** 
I 
II 
III 
III 
II 
II 
III 
I 
0 
I 
Cause of the 
hypertension 
renal 
renovascular 
essential 
essential 
renal 
renal 
renal 
essential 
renal 
essential 
Mean of 3 casual readings without medication 
Endogenous creatinine clearance 
Left ventricular hypertrophy, electrocardiographic criteria (16,17) 
Classification according to Keith, Wagener and Barker (13) 
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3 g in two patients). When after three days a stabilization was 
reached, control values (vide infra) were collected during the 
next three days. Thereafter oral diazoxide was started, 100 mg 
on the first day, 200 mg on the second day and 300 mg daily from 
the third to the 16th day. At day 7 propranolol was added, 40 mg 
t.i.d., and the dose was increased to 80 mg t.i.d., from day θ 
to 12. Then propranolol was discontinued, whereas diazoxide was 
continued for another four days. 
Measurements included daily body weight, heart rate, and su­
pine blood pressure (four readings daily) with a legally stamped 
sphygmomanometer (Erkameter 300). Phase V of the Korottkof sounds 
was considered as the diastolic blood pressure. Furthermore 
supine blood pressures were daily registered with an automatic 
device (Artenosonde 1217) during 30 minutes at two minute inter­
vals. Mean values were calculated from these measurements with 
exclusion of the first two and the last readings. 
In seven patients blood for determination of creatinine and 
plasma renin activity (PRA) (8) was drawn before diazoxide, 
before addition of propranolol, on the last day of propranolol 
medication, and on the day before diazoxide was discontinued. 
Blood for PRA was taken at noon after 3 hours of ambulation (9). 
Urine was collected for determinations of 24 hr creatinine and 
sodium excretion. 
Mean arterial pressure (MAP) was calculated as the sum of the 
diastolic blood pressure and one-third of the pulse pressure. 
Results are given as means + SEM. 
Levels of statistical significance were assessed using 
Student's t-test for paired observations and the correlation co­
efficient according to Pearson. P-values below 5 percent were 
considered to be significant. 
RESULTS 
Figure 1 shows the mean values of systolic and diastolic 
blood pressure as measured with the Artenosonde during the treat­
ment periods. Diazoxide induced a mean decrease in MAP of -12.9 
+ 2.4% (mean of days 4, 5, and 6). Addition of the ß-blocker 
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blood 200 
pressure ( mmHg ) 
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120 
8 0 -
cumulative 600 
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weight з о 
( k g ' ρ η 
4 0 0 
2 0 0 
serum 400 η 
creatinine ( μΜΠ ) 
320 
240 
propranolol 240 
(mg/24h ) 
diazoxide 
( mg/24h ) 
3 0 0 
F i g . 1. Changes m blood p r e s s u r e , cumulative sodium balance and body weight, 
and serum c r e a t i n i n e in the 10 p a t i e n t s during t reatment with o r a l 
diazoxide and p r o p r a n o l o l . Means +_ SEM are given. 
p r o p r a n o l o l caused a f u r t h e r d e c r e a s e i n MAP of -24.4 + 2 . 3 % 
(mean of days 9, 10, and 1 1 ) . As can be seen from F i g u r e 1, t h i s 
e f f e c t of p r o p r a n o l o l came t o complete e x p r e s s i o n immedia te ly 
a f t e r t h e s t a r t of t h e drug on day 7. The t o t a l MAP d e c r e a s e of 
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the combination of diazoxide and propranolol was -35.6 + 3.8% on 
day 7. After withdrawal of propranolol on day 11 the blood pres­
sure went up gradually. The mean MAP remained slightly, but not 
significantly, under the values that were initially reached with 
diazoxide alone (MAP decrease -13.7 + 2.4% as compared to control 
values). After discontinuance of diazoxide the blood pressure 
returned almost immediately to the control value. 
Figure 1 further shows the sodium retention and the concomi­
tant increase in body weight during the whole study. The sodium 
balance became positive to a mean of plus 550 mM and the mean 
total increase in body weight was 2.4 kg or 5.4% (range 0-10%). 
The hypotensive effect of diazoxide did not decrease despite a 
mean sodium retention of 22 3 mM and an increase in body weight of 
1.4 kg. The same held for the second period during which propra­
nolol was added. In this period there was an extra sodium reten­
tion of 230 mM without any decrease in the antihypertensive 
effect of the drug combination. The steady rise in the blood 
pressure after withdrawal of propranolol was accompanied by a 
smaller increment of sodium retention and was most likely related 
to the slow disappearance of the antihypertensive activity of the 
S-blocker. 
The increase m serum creatinine levels, as shown in Figure 1, 
is in accordance with our earlier observations (19). This increase 
was significant both during diazoxide alone (+16.1 + 3.3%) and 
after addition of propranolol (+35.9 + 7.0%). The increase in 
creatinine correlated significantly with the percentual decrease 
in MAP (r = -0.70; ρ < 0.001). As we have previously shown (19), 
the creatinine levels returned to control values after discontinua­
tion of the antihypertensive treatment. 
Although there was a small difference between the automatic 
and the hand-measured blood pressure values, the changes in MAP 
measured by either method showed a highly significant correlation 
(r = 0.80; ρ < 0.001). The sphygmomanometer blood pressures during 
the experimental periods are listed in Table II together with the 
heart rates and PRA. Diazoxide caused an increase in both heart 
112 
TABLE II. Chan jes in supine Ыооз. press ¿re, heart rate and 
РИА* duñng the different treatment penods 
Treatment periods 
Supine blood pressure (mmHg) 
(sphygmomanometer) 
Heart rate 
(beats/min) 
PRA** 
(ng/10 n.1/3 h) 
1 control 199/131 + 9/5 81 + 3 142 + 30 
2 diazoxide 176/116 + 7/3 97 + 3 233 + 38 
3 diazoxide and propranolol 
day 7 (see Fig. 1) 136/91 + 8/4 
days 9, 10,and 11 134/89 + 5/3 
76 + 3 
72 + 3 90 + 12 
4 diazoxide 
5 control 
178/111 + 9/4 
202/129 + 8/4 
95 + 2 
77 + 3 
179 + 32 
In seven out of ten patients 
Blood drawn at noon after 3 h ambulation (9) 
Means + SEM are given 
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rate (+20.1 + 4.8%) and PRA (+84 + 20%). Propranolol induced a 
decrease in heart rate to -11.0 + 3.5% below the control value 
and of PRA to -23 + 16% below the control value. The decrease in 
heart rate was present at the same day when treatment with pro-
pranolol was started. After withdrawal of propranolol both heart 
rate (+18.4 + 3.9%) and PRA (+28 + 15%) rose above the control 
value. All above mentioned changes were significant. 
The changes in MAP did not significantly correlate with the 
changes of either heart rate or PRA. 
Three patients complained of palpitations during the use of 
diazoxide alone (heart rates 110, 112 and 116 beats per min). 
In two patients manifest edema developed, with body weight in-
creases of 4.3 and 3.4 kg respectively. 
DISCUSSION 
In this short term study addition of propranolol to diazoxide 
induced an impressive further decrease of the blood pressure. 
Although propranolol has an antihypertensive effect of its own, 
analysis of our results leads to the conclusion that this effect 
cannot explain the decrease of 24.4% observed in our study. The 
decrease in blood pressure occurred on the very day that propra-
nolol was started, whereas the time required for propranolol to 
induce its optimal hypotensive effect, when the drug is used alone, 
is at least a few days or weeks (3,5). The maximal effect of 
treatment with propranolol alone is in the range of a blood pres-
sure decrease of 10% (2,7,12,20), which is less than half of the 
mean decrease after addition of propranolol to diazoxide in our 
study. It seems, therefore, more likely that, in combination 
with diazoxide, propranolol exerts its effect mainly by suppres-
sing reactions compensatory to the vasodilator treatment (6,14). 
We assume that the antagonizing effect of propranolol is predomi-
nantly directed against the increase in cardiac output which 
follows the use of vasodilators. This antagonism is reflected in 
a decrease in heart rate. The decrease in PRA may also contribute 
to the hypotensive effect. Since propranolol inhibits, however, 
both heart rate and PRA (5), it cannot be determined with certain-
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ty which of either plays the major role (8). The sodium retention, 
which almost invariably occurs after diazoxide, did not important-
ly antagonize the antihypertensive effect of the drug. The blood 
pressure did not rise in the first two treatment periods despite 
a positive sodium balance. 
In earlier studies we found a reversible decrease in renal 
function during antihypertensive treatment with diazoxide, after 
both intravenous (18) and oral (19) administration. This study 
confirms that finding and suggests that it is related to the 
decrease in blood pressure. The improvement in renal function 
after discontinuance of propranolol, while diazoxide was con-
tinued, gives further support for that relationship and argues 
against a direct nephrotoxic effect of diazoxide. 
In conclusion, the results suggest that the increase in car-
diac output and possibly the increase in PRA play an important 
role in antagonizing the antihypertensive efficacy of vasodilators 
and that propranolol mainly acts by a blockade of these compen-
satory reactions. Our study cannot unravel the separate contri-
butive roles of the changes in heart rate and PRA, since no sig-
nificant correlations were found between the changes in MAP and 
each of these parameters. The effect of a low dose of propranolol 
became already apparent on the first day of treatment. This makes 
it likely that in combination regimens with vasodilators, rela-
tively low doses of propranolol may be sufficient. The antago-
nistic action of the sodium retention on the other hand, seems 
relatively small and may even be negligible. 
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The non-diuretic benzothiazine, diazoxide, is used as an antihypertensive 
drug, especially for the intravenous treatment of hypertensive crises. It is 
recommended to administer the drug as a bolus injection, 300 mg within 
10—30 sec [1] , but recently it was shown that also an infusion during 20—30 
min was effective [2] and could avoid hypotension and consequent myocardial 
ischaemia. Orally administered diazoxide is seldom used for chronic treatment 
of severe hypertension. 
No clear relationship has been established between plasma concentration, 
half-life (Ti^) of elimination and vascular activity [1] . In hypertensive patients, 
the Tiyjj of elimination varies markedly between 21 and 50 h [1, 3,4] .The large 
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variation in pharmacokinetics observed may be as much related to analytical 
problems as to inherent variations in the patients. Currently analysis is carried 
out by a simple UV method [1, 3, 5], which is of low specificity since possible 
metabolites may have the same absorption characteristics. Sadee et al. [6] 
developed an excellent gas chromatographic—mass spectrometric (GC—MS) 
method for measuring diazoxide plasma concentrations but access to such 
equipment and the availability of the deuterated internal standard makes the 
assay difficult for routine applications. Grevink and Fleuren [7] developed a 
gas—liquid chromatographic method, which required derivatization of 
diazoxide as the methyl derivative. Both methods are quite laborious and the 
large series of samples that are required in kinetic studies or with therapy 
compliance control pose considerable methodological problems. 
High-performance liquid chromatography (HPLC) combines simple UV 
detection with chromatographic specificity. The method is somewhat less 
specific than GC—MS but its simplicity, speed and the possibility of analysing 
large series of blood samples are advantages. An HPLC method for the analysis 
of diazoxide was developed for the purpose of studying pharmacokinetics of 
diazoxide in healthy human volunteers, hypertensive patients and control of 
therapy compliance, and some results of the pharmacokinetics of diazoxide in 
healthy volunteers are reported. 
MATERIALS AND METHODS 
Apparatus 
A Spectra Physics 3500B high-performance liquid Chromatograph was used, 
equipped with a spectrophotometric detector (Model 770). The detector was 
connected to a 1-mV recorder (BD 7, Kipp en Zonen, Emmen, The 
Netherlands). A stainless-steel column (10 cm Χ 4.6 mm I.D.) was packed with 
LiChrosorb RP-8, particle size 5 μτη, obtained from Chrompack (Middelburg, 
The Netherlands). An injection loop of 100 μΐ was used. Detection of diazoxide 
was effected at 270 nm. The detection limit of diazoxide is 0.1 jug/ml. 
Solvents 
For diazoxide as a simple drug the solvent was a degassed mixture of 300 ml 
water and 200 ml methanol. The solvent flow-rate was 1 ml/min, at a pressure 
of 125 atm. (ft' diazoxide = 4.4.) 
For diazoxide with comedication of chlorthalidon, the solvent was a 
degassed mixture of 325 ml of 0.005 M sodium acetate and 175 ml of 
methanol, (ft' diazoxide = 5.75; ft' chlorthalidon = 3.25.) 
Sample preparation 
Plasma. Plasma (100 μΐ) is mixed with 400 μΐ of perchloric acid (0.33 N) on 
a Vortex mixer. Deproteinization is completed after standing for 5 min. The 
mixture is centrifuged for 5 min at 4000 rpm (2600 g) in a Heraus Christ 
centrifuge; 100 μΐ of the supernatant are injected onto the column. 
Urine. Urine (10 jul) is mixed with 500 μΐ of perchloric acid (0.33 N) on a 
Vortex mixer; 100 μΐ of the mixture are injected onto the column. 
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Drugs 
Diazoxide was obtained from Schering (Essex Nederland B.V., Amstelveen, 
The Netherlands). 
Subjects and patients 
Two healthy Caucasian subjects, both employees of the Department of 
Nephrology, volunteered for this study. Blood samples for routine control or 
pharmacokinetics studies in hypertensive patients were obtained from patients 
in the Department of Nephrology. Doses of 25, 100, 100 and 200 mg diazoxide 
were administered intravenously (i.v.) to the volunteers. Blood samples of 1 ml 
were taken at regular time intervals by venipuncture. 
Spontaneously voided urine was collected for 60 h. One volunteer excreted 
the drug under acidic urinary conditions achieved by the daily intake of 8 g of 
ammonium chloride. The other volunteer excreted diazoxide under alkaline 
urinary conditions maintained by the intake of 10 g of sodium bicarbonate per 
day. 
Recovery 
The recovery of diazoxide from plasma was 83.7 ± 1.2% (S.D.) at a 
concentration of 10 Mg/ml and 83.1 ± 2.8% (S.D.) at 5 Mg/ml; from urine it was 
98.1 ± 1.2% (S.D.). 
The calibration curves were obtained by adding known amounts of diazoxide 
to human plasma and urine samples. They were linear for the concentration 
range 0.10 50 μβ (r = 0.998). The sensitivity limit was 0.1 Mg/ml. 
RESULTS 
Fig. 1 shows a chromatogram of two different human plasma samples 
containing diazoxide. The second peak (X ) is an endogenous compound as it 
appeared in the plasma of both volunteers and patients, and is sometimes 
present in markedly varying concentrations in plasma of patients and 
volunteers who did not receive diazoxide. 
Fig.' 2 shows the plasma concentration, salivary concentration and rerial 
excretion rate—time profiles in a volunteer after an intravenous dose of 100 mg 
of drug under alkaline urinary conditions. The half-life of elimination in the 
volunteers varies from 15 to 20 h. The ratio between the concentration of 
diazoxide in plasma and saliva is found to be constant in each volunteer, but 
varies between 1.5 and 4.8. 
The two human volunteers excreted about 20% of the drug unchanged after 
all doses (Table I). The relationship of renal excretion rate ^g/min) to the 
plasma concentration (/ig/ml) appeared to be linear, showing an average renal 
clearance constant of 5.36 ml/min, as shown in Fig. 3. The renal clearance of 
diazoxide was calculated from each urine sample and corresponding plasma 
sample and plotted against urine flow or urinary pH. 
When the urinary pH is not modified by the intake of ammonium chloride or 
sodium bicarbonate the renal clearance—urinary pH relationship shows a 
relatively high correlation coefficient (Table I). In both cases the renal 
clearance is also dependent on the urine flow (Fig. 4). The average renal 
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clearance over the whole time course of the elimination process of diazoxide is 
low (2—6 ml/min). The calculated pharmacokinetic parameters of diazoxide are 
summarized in Table I. 
diazoxide 
ЭС002 A 
47 
blank 
hi^nan 
pasma 
00002 A 00002 A 
20ijg,"-il 
η 
Human 
plasma 
-u 
Fig. 1. Chromatogram of diazoxide (D) as single medication in a human plasma sample. 
Compound x is an endogenous compound present in markedly varying concentrations. 
Solvent: 300 ml water—200 ml methanol. Solvent flow-rate: 1 ml/min. Column: LiChrosorb 
RP-8, 5 μπι particle size. 
DISCUSSION 
The HPLC method is found to be reliable and extremely simple and it 
exhibits a good sensitivity limit of 0.1 μg/.ml. This value is between the 
sensitivity limit of the UV method of Symchowicz et al. [4] and that of the 
GC -MS method of Sadee et al. [6] (10 ng/ml). Even with a subclinical dose of 
25 mg i.V., the plasma concentration elimination curve is followed for 60 h, 
which is long enough for estimation of Гі^  values. 
The low renal clearance of the unchanged drug implies high protein binding, 
strong tubular reabsorption and therefore dependency on urinary pH and 
urine flow. Because of the low renal clearance, the main route of elimination 
therefore must be oxidation to a carboxylic acid, followed by glucuronidation 
and renal excretion. 
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diazoxide in man — 
renal excr rate pg/mrn 
plasme cone pg /m i 
urine How 
ml/mm 
Fig. 2. Plasma and saliva concentrations and renal excretion rate—time profiles of diazoxide 
after an i.v. dose of 100 mg in a volunteer There is a constant ratio (4.8) between the 
plasma and saliva concentration. The urinary pH in this experiment has been kept alkaline 
[pH7.70± 0.49 (S.D.)]. 
TABLE I 
SOME PHARMACOKINETIC PARAMETERS OF DIAZOXIDE IN MAN 
Subject 
T.Th. 
T.Th. 
F.H. 
F.H. 
Dose 
(mg, i.v.) 
25 
100 
200 
100 
Urine flow 
(ml/min 
± S.D.) 
0 .99 ± 0.30 
1.69 ± 0.76 
1.45 t 0.89 
2.61 ± 1.81 
Urine pH 
(* S.D.) 
6.19 ± 0.28 
7.70 ± 0.49 
6.42 ± 0.59 
5.34 ± 0.17 
Tv. 
(h) 
17 
15 
20 
16 
Percentage 
excreted* 
27.8 
16.5 
20.4 
14.7 
Renal 
clearance 
(ml/min 
± S.D.) 
6.70 ± 1.79 
2.05 ± 0.79 
3.50 ± 1.76 
3.25 ± 1.96 
*Percentage of the dose excreted in the urine unchanged. 
** Correlation coefficient relationship between urinary pH and renal clearance. 
***Correlation coefficient relationship between urine flow and renal clearance. 
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diazoxide in man - diazoxide in man -
Y . 1 6 3 X · 101 
r, 081 
L m l / m m 
Fig. 3. Linear relationship between the renal excretion rate dQ/df (pg/min) and plasma con­
centration C
a
 (Mg/ml) of diazoxide in man with uncontrolled urinary pH. The average renal 
clearance (if
r
) over the whole excretion period is 5.36 ml/min. 
Fig. 4. Relationship between the renal clearance of diazoxide (Κ
τ
) and the urine flow in a 
volunteer receiving 200 mg iv. The urinary pH is 6.42 i 0.59 (S.D.). 
The half-life of elimination in the two healthy volunteers did not vary much. 
The Tvi may be dependent on the renal function, since with impaired kidney 
function the Ti^  is prolonged to 40—50 h [8], but it also depends on the 
degree of hypertension [6] . 
The availability of a simple, reliable and fast analytical method for the 
measurement of diazoxide in human plasma samples may reveal the relation­
ships between dose, speed of injection, plasma concentration and blood 
pressure lowering effects. 
Ratio of 
plasma/ 
saliva 
concentration 
_ 
4.8 
1.5 
3.5 
г 
pH-if,. 
0.46 
0.22 
0.62 
0.020 
** now-tf
r
*** 
0.72 
0.38 
0.81 
0.22 
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SUMMARY 
In eight outclinic hypertensive patients a prospective study 
was performed to examine the hypotensive effects of oral dia-
zoxide and propranolol, both given separately and in combination. 
The patient compliance was controlled by determination of plasma 
levels of diazoxide. Diazoxide (250 mg daily orally) induced a 
mean arterial pressure (MAP) decrease of -6.5% as compared to 
placebo. Propranolol (240 mg daily) caused a MAP decrease of 
-10.2%. The combination of the drugs, however, decreased MAP with 
-24.2%, and this was significantly greater than the sum of the 
effects of the two drugs given separately (p < 0.05). The percen-
tual MAP changes were correlated with the diazoxide plasma levels 
(r = -0.67). During diazoxide alone almost all patients complained 
of palpitations, headache or restlessness. This was accompanied 
by a significant increase in heart rate. When diazoxide was added 
to propranolol neither increase in heart rate nor side-effects 
were observed. Both diazoxide and propranolol induced an increase 
in body weight and therefore furosemide had to be added. The in-
crease in body weight was most impressive during the phase of 
combined therapy. Diazoxide caused a reversible increase of crea-
tinine, which was of minor clinical importance. During treatment 
with directly-acting strong vasodilators like diazoxide 3-blockers 
are necessary to inhibit the sympathetic stimulation, and diure-
tics to prevent the sodium retention. 
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INTRODUCTION 
An abnormally increased peripheral resistance has been found 
in most forms of established hypertension (4,7). Therefore 
directly-acting vasodilator drugs such as hydralazine, minoxidil, 
or diazoxide seem to be the therapy of choice. These vasodilators 
induce, however, compensatory reactions, which antagonize the 
hypotensive effect. To obviate this problem, vasodilators are 
usually combined with diuretics and 3-adrenoreceptor blocking 
agents (12,19,26). Many authors report good results from this 
so-called triple therapy, and this concerns both the hypotensive 
effect and the reduction of side-effects (1,6,11,14,19,22,25,27). 
In a previous retrospective study we were able to confirm the 
effectivity and the lack of side-effects of such a regimen (19). 
The aim of this study was to examine the effect and side-effects 
of oral diazoxide alone, the effect of 3-blockade alone and the 
effect of their combination. Furthermore, the effects of diazoxide 
could be related to its plasma levels. 
PATIENTS AND METHODS 
Eleven patients originally entered the study after having 
given informed consent. In one patient the study was interrupted 
because of anginal complaints during diazoxide alone. In two 
patients the plasma levels of diazoxide were repeatedly below 
the therapeutic range (about 10 mg/1) and consequently these two 
patients were eliminated from the study. Table I lists the cli-
nical characteristics of the remaining eight patients. 
After discontinuance of all previous therapy the patients 
remained untreated for 4 weeks. The consecutive phases of the 
study were as follows: 
Phase 1 (4 weeks): placebo 
Phase 2 (6 weeks): oral diazoxide, 100 mg daily for 1 week, 
200 mg for 2 weeks and 300 mg for 3 weeks. When edema developed 
or body weight increased > 2.5 kg, furosemide was added. 
Phase 3 (4 weeks): no medication, no placebo. 
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TABLE 1. Clinical -hará •tenielias of the patients before the treatment -protocol 
Control blood pressures* ECC** 
2 
Patient Age Sex Sphygmo- Artcrio- ml/min/l.73m 
(yrs) manometer sonde 
LVH*** Hypertensive Hypertension 
re t iпора thy****Cause Known d u r a t i o n 
(yrs) 
1 43 F 104/130 192/130 102 essential 
54 F 222/116 195/114 90 essential 11 
3 21 F 152/102 143/108 119 renovascular 1/3 
40 M 225/142 200/152 101 essential 
5 38 M 158/116 152/111 95 essential 
26 F 100/125 160/126 153 essential 1/3 
63 M 183/100 190/113 61 essential 1/2 
28 M 170/122 158/115 128 renal 
ы 
ω 
blood pressures in mmHg 
endogenous creatinine clearance 
left ventricular hypertrophy, electrocardiographic criteria (14,15) 
classification of Keith-Wagener-Barker (9) 
Phase 4 (10 weeks): propranolol 120 mg daily for 2 weeks and then 
240 mg daily. 
Phase 5 (8-24 weeks): addition of oral diazoxide 100 mg daily and 
when the hypotensive effect was insufficient (diastolic blood 
pressure > 90 mmHg) 200 mg diazoxide daily. Furosemide as in 
phase 2. 
Phase 6 (8 weeks): discontinuance of diazoxide and furosemide. 
Propranolol alone, 240 mg daily. 
Thus, the study covered at least 40 weeks, but in some patients 
56 weeks (mean 50 weeks). During the protocol the patients were 
seen at weekly intervals at the outpatient clinic. At each visit 
blood pressure was measured in the supine patient at two minute 
intervals during 30 minutes, using the Artenosonde 1217. For 
evaluation, means of all readings were calculated, with omittance 
of the first two and the last readings. At the end of the auto-
matic measurements blood pressure was measured twice with a 
legally stamped sphygmomanometer (Erkameter 300), both in the 
supine and standing positions. Phase V of the Korotkoff sounds 
was taken as the diastolic blood pressure. Heart rates were also 
determined in both positions. Mean arterial pressure (MAP) was 
calculated as the sum of the diastolic and one-third of the pulse 
pressure. During all phases the correlation coefficients of the 
MAP determined with the two methods were greater than 0.80. 
Body weight was measured at each visit. All the measurements 
were performed by the same observer. 
At regular intervals, but especially when a change in the 
treatment schedule was planned, blood was drawn for determination 
of creatinine, uric acid, glucose, and diazoxide levels. Dia-
zoxide was determined according to the method described by Vree 
et al (23). 
The patients were on a liberal sodium intake and this appeared 
to vary from mean 83-20 8 mM daily, as evidenced from sodium 
determination in 24 hr urine samples (mean of 8 determinations 
per patient). During each phase of the study the patients were 
asked to complete a check-list of side-effects. 
Means of the data collected at the last three visits of each 
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treatment-phase were used for evaluation of the effects. Results 
are expressed as means + SEM, unless indicated otherwise. 
Statistical methods used were Student's t-test for paired ob-
servations and the correlation coefficient according to Pearson. 
P-values less than 5% were considered to be significant. 
RESULTS 
Adherence to the pro loco , 
In phase 2, four out of the eight patients were not able to 
tolerate 300 mg diazoxide daily (patients 2, 4, 5 and 6 in Table I). 
In these patients the effect of 200 mg diazoxide daily is used 
for evaluation. Six of the eight patients also used furosemide, 
mean daily dose 47 mg (range 20-80 mg). In phase 5, four of the 
eight patients (2, 3, 4, and 5 m Table I) were still hypertensive 
(diastolic blood pressure > 90 mmHg) on propranolol and 100 mg 
diazoxide and consequently the daily dose of diazoxide was in-
creased to 200 mg. Patient 1 temporarily used 300 mg diazoxide, 
but afterwards the dose could be decreased to 200 mg. During 
this phase the same six patients as in phase 2 used furosemide, 
mean daily dose 50 mg (range 40-80 mg). 
L·ffer is on blood pressure 
The upper panel of Figure 1 shows the mean Artenosonde blood 
pressures during the study. Expressed as mean percentual changes, 
MAP decreased -6.5+2.6% (p < 0.05) during phase 2, -10.2 +2.2% 
(p < 0.001) during phase 4 and -24.2 + 2.1% (p < 0.0001) during 
phase 5. The decrease during phase 5 was significantly greater 
than the sum of the decreases during phase 2 and 4 (p < 0.05) , 
despite the fact that the mean daily dose of diazoxide adminis-
tered in phase 5 was 100 mg less than in phase 2. Table II shows 
that in none of the treatment phases orthostatic hypotension was 
observed. 
Effects on heart rate and body wetght 
The lower panel of figure 1 shows the changes in heart rate 
and body weight during the study. Diazoxide induced a significant 
increase in heart rate (p < 0.05) whereas during propranolol 
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TABLE I I . o[/n0j'rOPÌ^.rlo,>,etCr bU^d pi'e.lv Ί'βΰ η ipirlL· 
und Biatidbíj d '""Zrij díj'jci'cní phasej 
Phases of supine standing 
treatment 
1 178/119 + 7/3 176/123 + 7/3 
2 1 7 1 / 1 1 1 + 6 / 5 1 7 3 / 1 1 6 + 5 / 5 
3 1 7 9 / 1 1 9 + 5 / 3 1 7 2 / 1 2 0 + 4 / 3 
4 161/104 + 7/4 156/105 +_ 5/4 
5 141/87 + 4/2 141/92 + 4/2 
6 164/104 + 7/4 158/109 + 6/4 
Means +_ SbM are given. 
h e a r t r a t e d e c r e a s e d t o v a l u e s s i g n i f i c a n t l y l o w e r t h a n t h e p l a -
c e b o v a l u e s (p < 0 . 0 0 1 ) . When d u r i n g p h a s e 5 d i a z o x i d e was a d d e d 
t o p r o p r a n o l o l , no s i g n i f i c a n t c h a n g e i n h e a r t r a t e was o b s e r v e d . 
Bo th d i a z o x i d e and p r o p r a n o l o l a l o n e i n d u c e d a s i g n i f i c a n t i n -
c r e a s e i n body w e i g h t (p < 0 . 0 1 ) . D i a z o x i d e a d d e d t o p r o p r a n o l o l 
l e d t o a f u r t h e r s i g n i f i c a n t i n c r e a s e i n body w e i g h t (p < 0 . 0 2 5 
a s c o m p a r e d t o p r o p r a n o l o l a l o n e ) . 
Plasma levels of diazoxide 
T a b l e I I I shows t h e i n d i v i d u a l d e t e r m i n a t i o n s of t h e p l a s m a 
l e v e l s , d u r i n g d i f f e r e n t d o s e s of d i a z o x i d e i n a l l 11 p a t i e n t s . 
The p l a s m a l e v e l s f o u n d m p a t i e n t s 9 and 10 p r o v e d , t h a t t h e y 
h a d t a k e n d i a z o x i d e a t l e a s t i r r e g u l a r l y . I n t h e s e two p a t i e n t s 
l e v e l s o f g r e a t e r t h a n 10 m g / 1 , w h i c h a r e c o n s i d e r e d t o b e t h e r a -
p e u t i c (2 ) , w e r e o n l y a t t a i n e d i n c i d e n t a l l y i n p h a s e 5 . From t h e 
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Fig. 1. Blood pressures, heart rates and percentual changes in body weight 
during the subsequent phases of treatment. Means + SEM are given. 
d a t a i n Table I I I i t can be concluded t h a t t h e m t e r - p a t i e n t 
v a r i a t i o n d u r i n g t h e same dose of d i a z o x i d e may be l a r g e , b u t t h a t 
t h e v a r i a t i o n i n each i n d i v i d u a l p a t i e n t d u r i n g t h e same dose i s 
r a t h e r s m a l l . F i g u r e 2 shows t h e r e l a t i o n between t h e mean p l a s ­
ma l e v e l s a t a g iven d a i l y dose of d i a z o x i d e and t h e mean p e r ­
c e n t u a l d e c r e a s e i n MAP. Al l t h e s e d a t a were o b t a i n e d d u r i n g 
phase 5, and t h e MAP i s e x p r e s s e d as p e r c e n t u a l change from phase 4. 
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TABLE in. Plasma Levels of diasoxiae dupù^j different 
doses of diazoxide in 11 patients 
Patient Dose of diazoxide Consecutive plasma levels 
(mg/24 h) of diazoxide (mg/l) 
1 100 21.3,24.5 
200 43.5,27.0 
300 79.0 
2 100 12.8,10.0,9.0 
3 100 9.0,11.3,11.5,10.0 
200 18.5 
4 100 22.0,25.0,28.5 
150 37.0,40.5,36.0 
200 43.5,46.9 
5 100 11.8 
6 200 24.0,24.0,19.5,27.5,25.0,17.0 
7 100 9.0 
200 39.5 40.5,30.0,28.0 
8 100 10.0,12.5,9.0 
200 19.0 
9* 100 1.3 
200 11.0,5.0, 11.0,<0.5, 13.5,6.5 
10* 200 3.6,5.5,4.0,10.5 
300 <0.5 
11** 200 21.0,26.0,23.0,19.0,29.0,25.0 
300 46.5 
* Patients were left out from the evaluation because of irregular or 
insufficient compliance 
** The patient with anginal complaints, in whom the study had to be 
interrupted 
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Fig . 2. Relat ion between plasma diazoxide l e v e l s , the d a i l y dose of diazoxide 
and the percentua l changes in MAP. Means + SEM are given. 
When t h e i n d i v i d u a l plasma l e v e l s of d i a z o x i d e were c o r r e l a t e d 
w i t h t h e c o r r e s p o n d i n g p e r c e n t u a l MAP changes t h e c o r r e l a t i o n c o ­
e f f i c i e n t amounted -0 .67 (n = 33, ρ < 0 . 0 0 1 ) . Thi s s i g n i f i c a n t 
c o r r e l a t i o n was found i n s p i t e of t h e l a r g e i n t e r - p a t i e n t v a r i a ­
t i o n a t a g iven d o s e . 
Effects of biochemical parame levs 
Table IV shows t h a t t h e r e were no g r e a t changes i n t h e b i o ­
chemica l p a r a m e t e r s . Although the changes were s i g n i f i c a n t d u r i n g 
phase 5, they were of minor c l i n i c a l i m p o r t a n c e . The h i g h e s t 
g l u c o s e l e v e l s observed were 9.6 and 8.5 mM/1 i n p a t i e n t s 4 and 7, 
who had a l r e a d y an i m p a i r e d g l u c o s e t o l e r a n c e b e f o r e t h e s t u d y . 
Side-effects 
Table V l i s t s t h e i n c i d e n c e of s i d e - e f f e c t s as r e c o r d e d by t h e 
p a t i e n t s on t h e c h e c k - l i s t s . Only s i d e - e f f e c t s t h a t were mentioned 
a t l e a s t twice d u r i n g a t r e a t m e n t p e r i o d and n o t i n t h e p l a c e b o 
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TABLE IV. ¡•abofaiispy ¡Julucs 
Phase Plasma creatinine 
(μΜ/1) 
Blood glucose 
(mM/1) 
Uric acid 
(пМ/1) 
91 + θ.1 
97 + 8.5* 
94+8.1 
93 + 7.4 
101 + 7.8* 
92 + 8.0 
5.1 + 0.14 
5.8 + 0.53 
5.4 + 0.32 
5.1 + 0.14 
6.4 + 0.60* 
5.0 + 0.16 
0.33 + 0.02 
0.35 + 0.03 
0.31 -+0.02 
0.33 + 0.02 
0.39 +0.04* 
0.32 + 0.02 
Significant when compared to placebo values 
Means + SEM are given 
TABLE v. L'jidc-effoiiiu of diazoxide in difj'erenc рпазес 
Giazoxide alone propranolol alone combination 
palpitations 
headache 
nervousness/restless­
ness etc.* 
nausea, vomiting 
edema 
hypertrichosis 
tiredness 
Spontaneously noted with different descriptions (see text) 
period are g iven. Apart from the s i d e - e f f e c t s on the l i s t , s i x 
p a t i e n t s spontaneously noted f e e l i n g s that were descr ibed as 
t e n s i o n , nervousness, r e s t l e s s n e s s , i r a s c i b i l i t y or a n x i e t y . 
When d iazoxide was combined with propranolol the s i d e - e f f e c t s 
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were almost completely absent. The side-effects noted during pro-
pranolol alone were of minor clinical importance. 
DISCUSSION 
Most literature reports (1,5,6,8,9,19,25,27) describe a good 
hypotensive effect of the directly-acting vasodilators, when given 
in combination with a 3-blocker. In nearly all these studies the 
patients further used a diuretic, in some studies already before 
the start of the regimen (3,17,20,22). In none of these studies 
oral diazoxide was used as the oral vasodilator. This study anal-
yses the separate effects of the components in the commonly used 
triple drug regimens in hypertension. The results demonstrate 
that the hypotensive effect of the combined use of diazoxide and 
propranolol is greater than the sum of the effects of the sepa-
rately used drugs. Although complete dose response studies were 
not performed with either drug alone it is most likely that there 
is a synergistic action of the two drugs. This can, at least part-
ly, be explained by the fact that the ß-blockers inhibit the com-
pensatory reactions, which are observed when directly-acting 
vasodilators are used alone (12). This assumption is supported by 
the differences m side-effects found during the respective phases 
of treatment. Most of the complaints seemed to be caused by an 
increase in sympathetic tone as a consequence of diazoxide ad-
ministration. The addition of a 3-blocker prevents these side-
effects almost completely by suppression of the sympathetic sti-
mulation of the heart. This is clearly illustrated by the lack 
of an increase in heart rate during the combined treatment. This 
finding is in contrast with the effect of intravenous diazoxide 
added to propranolol (13). 
The study demonstrates that diazoxide alone, like other direct-
ly-actmg strong vasodilators (20) is unsuitable for the chronic 
treatment of hypertension. Although Brunner et al (5) suggest 
that the g-blocker may be discontinued in some patients when 
combined treatment has been given for longer periods, Watkins et 
al (24) have found that one should be careful with such changes 
in therapy. On the other hand when ß-blockers are only given to 
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suppress the compensatory reactions and the side-effects, lower 
doses might be sufficient (5,21). 
The increase in body weight during diazoxide therapy demon-
strates that the drug induces an increase in extracellular volume 
(8,21). Therefore apart from the vasodilator and the 3-blocker, 
either a low salt intake or addition of a diuretic is necessary. 
The monitoring of a therapeutic regimen with plasma levels of 
the drug may give an insight in the compliance of the patients 
and makes it possible to correct for individual variations in 
absorption. It is instructive that even in this carefully con-
trolled study for which cooperative patients were selected, who 
were amply informed, two out of 10 patients appeared to have a 
low compliance. These were also the only two patients, who did 
not have complaints during diazoxide alone. They also failed to 
show a hypotensive effect during phase 2. 
In accordance with our earlier studies (18,19,21) we found a 
reversible decrease in renal function. In the patients studied 
here the increases in plasma creatinine were rather small, pro-
bably because the patients had only slight or no impairment of 
renal function at the start of the treatment. 
It should be mentioned that most of the other side-effects 
occurring in this study were especially important to demonstrate 
the beneficial influence of 3-blockade. After long-term treatment 
hypertrichosis is a troublesome side-effect of strong vasodilators. 
Furthermore, diazoxide may induce a hyperglycaemia (2,19), that 
requires treatment with oral antidiabetic drugs. 
In conclusion this study demonstrates that the use of direct-
ly-acting vasodilators for the treatment of hypertension can 
only be effective, and will only be tolerated by the patients, 
when given in combination with a ß-blocker to suppress the sym-
pathetic stimulation and with a diuretic for inhibition of the 
sodium retention. 
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Chapter Χ 
GENERAL SUMMARY 
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Treatment of hypertensive patients with antihypertensive drugs 
has proved to cause a substantial reduction of cardiovascular 
complications. Such treatment is indicated in most patients with 
hypertension, since there is only a minority of less than 10% in 
whom the cause of the hypertension can be identified and who 
can be treated by other means. It is therefore of prime importance 
to develop drugs that are effective antihypertensive agents with-
out having important side-effects. For many patients with mild 
or moderate hypertension diuretic drugs and g-adrenoreceptor 
blocking agents, whether used alone or m combination, do ful-
fill this need. However, for a small group of patients with 
marked or severe hypertension another approach is required. 
The most constant haemodynamic abnormality in established 
hypertension is the existence of an increased peripheral vascu-
lar resistance. On theoretical grounds, therefore, drugs that 
induce vasodilation and especially those, which do so by a direct 
relaxation of vascular smooth muscles, would deserve a prominent 
place in the treatment of hypertension. These latter drugs are 
called (directly-acting) vasodilators and they generally exert 
their greatest activity on the precapillary resistance vessels. 
Vasodilators, however, have not been widely used m the past 
because monotherapy with these drugs is not readily tolerated. 
Undesirable effects and decreased efficiency develop in most pa-
tients. These are caused by three compensatory mechanisms: 1) an 
increase in sympathetic tone, resulting in an increased cardiac 
output, 2) stimulation of the renin-angiotensin system, and 3) 
sodium retention. These compensatory reactions have to be anta-
gonized by the addition of other drugs. This makes the treatment 
more complicated and has precluded vasodilating drugs from be-
coming first choice agents for the chronic treatment of hyper-
tension. The only situation in which vasodilators can be used 
without additional agents is in the treatment of acute hyperten-
sive emergencies. 
Since 1974 we have used the strong vasodilator diazoxide for 
both acute and chronic treatment of patients with severe hyper-
tension. The drug induces relaxation of the vascular smooth 
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muscles by an interaction with calcium, which is necessary for 
the contraction mechanism. Recent studies suggest that the drug 
blocks the release of calcium from its intracellular stores. 
Initially diazoxide was used as a single drug only for the 
treatment of patients with a hypertensive crisis. The drug was 
administered in a dose of 300 mg and it was given as a bolus in-
jection (within 10-30 seconds), because several investigators 
had shown that slower administration was ineffective. The bolus 
injection caused an immediate and precipitous fall of the blood 
pressure. We found a 25 to 30% decrease in blood pressure and 
this effect lasted for 8 to 10 hours. Although this effect was 
highly satisfactory, the rapid and often unpredictable fall of 
the blood pressure that occurred immediately after the injection 
remained a considerable disadvantage, rurthermore, there appeared 
reports of serious myocardial and cerebral complications, that 
were possibly related to this sudden drop in blood pressure. This 
led us to restudy the efficacy of diazoxide administered as a 
slow infusion. The infusion rate was 15 mg/min and a total dose 
of 5 mg/kg was administered. In contrast to the current opinion 
we found that these infusions were as effective as the bolus in-
jections in the treatment of patients with a hypertensive crisis. 
The technique had the obvious advantages of a more gradual decline 
of the blood pressure and of interruption of the infusion when 
too large a fall of the blood pressure made this necessary. 
Cardial or cerebral complications have not been observed in the 
40 patients that have been treated in this way up to this moment. 
Among patients with acute hypertensive emergencies those, who 
present with (pre-)eclampsia seemed to form a special group. The 
sensitivity to the antihypertensive effect of diazoxide was sig-
nificantly greater in this group than in non-pregnant patients. 
The factors that might be responsible for this difference were: 
a lower age, a lower initial blood pressure and a shorter duration 
of the hypertensive disease. Furthermore, the pregnant patients 
had lower serum protein concentrations, which might allow for 
higher levels of free diazoxide in the circulation. This greater 
sensitivity obviously exposes the patient to an increased risk 
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of severe hypotension after a bolus injection. We found that 
especially the systolic blood pressure showed an exaggerated fall. 
In these patients slow infusion also induced a more gradual de-
cline of the blood pressure, whereas the hypotensive effect 
eventually reached was similar to that of the bolus injection. 
Even infusion rates as slow as 7.5 mg/min proved to be effective 
in these patients. Our experience makes it clear that if diazoxide 
is used in hypertensive emergencies, administration of the drug 
by infusion is the preferred treatment under all circumstances. 
The experience with oral diazoxide in enrome antihypertensive 
treatment is limited. Because the drug causes hyperglycaemia and 
hypertrichosis it has been used only in patients in whom the 
hypertension was resistant to all other therapy. Our experience 
now covers 125 patients and in some of these the follow-up period 
has exceeded 5 years. The drug was almost exclusively used in 
combination with a g-adrenoreceptor blocking agent, to antagonize 
the compensatory tachycardia. Sodium retention occurred in nearly 
all patients but was controlled with diuretics. Both systolic and 
diastolic blood pressure decreased by 25 to 30%. "En nearly all 
patients there was an initial decrease in renal function, and this 
was especially so in those in whom renal function was already 
compromised. Since such a decrease has been found with other anti-
hypertensive regimens and occurs concomitantly with the initial 
fall in blood pressure, it is unlikely that it is due to a direct 
nephrotoxic effect of diazoxide. Moreover, renal function returned 
to its pretreatment level in patients in whom diazoxide was dis-
continued. In the patients, who developed hyperglycaemia, a well-
known side-effect of diazoxide, this could be easily treated with 
tolbutajnide. Hypertrichosis was the most troublesome subjective 
side-effect, especially in females and in young patients. The 
excessive hair growth always disappeared after discontinuation of 
diazoxide. Apart from this latter side-effect, the drug was well 
tolerated. This was not m the least caused by the absence of 
orthostatic or exercise-induced hypotension. Many patients had 
suffered from this complication, while on previous antihyperten-
sive regimens. 
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In a small group of hospitalized hypertensive patients a ß-
adrenoreceptor blocker was added during five days to diazoxide 
(300 mg daily, orally) and the effects on blood pressure, heart 
rate and PRA were studied. Already on the first day, that pro-
pranolol was added, the maximal hypotensive effect of the combi-
nation was obtained and the extent of this effect clearly exceeded 
the hypotensive effect of propranolol when used alone. This 
favourable interaction can be ascribed to the inhibition of the 
sympathetic stimulation caused by the directly-acting vasodilator 
diazoxide. Since propranolol reduced both heart rate and PRA and 
no correlations could be found between the changes in blood pres-
sure and the changes of these two parameters, we could not deter-
mine which of either plays a dominant role in antagonizing the 
hypotensive action of diazoxide. The antihypertensive effects in 
this study occurred in spite of sizable increases in body weight 
suggesting that compensatory sodium retention does not greatly 
antagonize the antihypertensive action of the vasodilator. 
The pharmacokinetics of diazoxide have not been widely studied, 
because of the lack of a simple method for its determination. 
Using high pressure liquid chromatography a fast and reliable 
method for the measurement of diazoxide was developed. Its sensi-
tivity limit was 0.1 mg/1, which makes it possible to measure 
plasma half-lives after intravenous dosages as low as 25 mg. The 
half-life in normal volunteers ranged from 15 to 20 hr with renal 
clearances of 2 to 6 ml/min. At a given oral dose plasma levels 
in patients with impaired renal function and normal controls 
were similar. The method was not only useful to monitor patient 
compliance during oral treatment, but served also to study the 
relationship between plasma levels and the antihypertensive 
effect. This determination of plasma levels of diazoxide was used 
in a prospective outclinic study which was undertaken to deter-
mine the effect of oral diazoxide and propranolol alone and of 
their combination. Eight patients completed the study that lasted 
almost one year. The effect of the combination was significantly 
greater than the sum of the effects of the two drugs given 
separately. The plasma diazoxide levels showed a significant 
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correlation with the percentual decrease in MAP. With the plasma 
determinations two patients could be identified who did not take 
the drug regularly. They were left out from the evaluation. 
Apart from the synergistic effect on blood pressure of the two 
drugs great differences in side-effects were observed between the 
phase with diazoxide alone and the phase wherein diazoxide was 
added to the ß-blocker propranolol. All patients had serious com-
plaints during the use of diazoxide alone. When diazoxide was 
added to propranolol only one patient had minor complaints. 
Directly-acting strong vasodilators such as diazoxide can only 
be used effectively if they are combined with a ß-blocker (to 
suppress the sympathetic stimulation) and with a diuretic (to pre-
vent sodium retention). 
Our studies show that strong vasodilators,such as diazoxide, 
are useful for rhe treatment of severe hypertension. They have 
become indispensable for the nephrologist because especially in 
patients with renal disease hypertension is often difficult to 
control. For acute treatment, diazoxide given by infusion seems 
an almost ideal approach. In chronic protocols the drug is also 
highly effective provided the compensatory reactions are inhibited. 
Unfortunately, some other side-effects prevent it from becoming 
the drug of first choice for this purpose. This implies that there 
is still a need for new strong vasodilators. The treatment proto-
cols as described in this thesis may serve as useful models to 
test such newly developed drugs. 
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STELLINGEN 
1 
Intraveneuze toediening van diazoxide aan patiënten met een 
hypertensieve crisis dient in de vorm van een langzaam lopend 
infuus plaats te vinden. 
Dit proefschrift. 
2 
Bij zwangeren met een hypertensieve crisis is de reaktie van de 
bloeddruk op intraveneus toegediend diazoxide sterker dan bij 
niet-zwangeren met een hypertensieve crisis. 
Dit proefschrift. 
3 
Indien diazoxide en propranolol gezamenlijk per os worden toege-
diend, is het effect op de bloeddruk groter dan de som van de 
effecten van elk middel afzonderlijk. 
Dit proefschrift. 
4 
In t e g e n s t e l l i n g t o t de gangbare mening kan men de r e a k t i e op 
een s a r a l a s i n e - i n f u u s n i e t gebru iken om t e v o o r s p e l l e n of c h i r u r -
g i s c h e c o r r e c t i e van een n i e r a r t e r i e s t e n o s e t o t v e r l a g i n g van de 
b loeddruk z a l l e i d e n . 
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Hollifield (1977) Saralasin infusion in the recognition of renovascular 
hypertension. Ann. Intern. Med. 87, 36. 
Th. Thien, W.H.L. Hoefnagels (1980) Saralasin infusion in renovascular 
and essential hypertension. Neth. J. Med. (in press) 
5 
Voordat een behandeling met hydralazine wordt begonnen, verdient 
het aanbeveling het acetylator-fenotype van de patient te bepalen. 
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Het effect van hydralazine (150 mg/dag) op de bloeddruk, uitgedrukt als 
procentuele daling van de gemiddelde arteriële druk (MAP) bi] 15 "langzame" 
en 14 "snelle acetyleerders". 
(eigen niet gepubliceerde waarnemingen) 
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Kasuis t ik mu l t i p l e r abdominaler und ze reb ra l e r Gefässveränderungen. 
For t sch r . Rontgenstr . 126, 3, 218. 
7 
De opvatting, dat een behandeling met antithymocytenglobuline 
slechts zinvol is indien ingesteld vöór het manifest worden van 
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een t r a n s p l a n t a a t r e s e c t i e , i s o n j u i s t . 
A.D. Mee and D.B. Evans (1970) Antilymphocyte-serum preparation in 
treatment of renal-allograft rejection. Lancet 2, 16. 
M.A. Hardy, R. Nowygrod, A. Elberg and G. Appel (1980) Use of ATG in 
treatment of s teroid-resistant rejection. Transplantation 29, 162. 
Α. Hoitsma, persoonlijke mededeling. 
8 
De hoge b l o e d s p i e g e l s van c a l c i t o n e b i j sommige p a t i ë n t e n 
met een g a s t n n o o m z i j n n i e t h e t gevolg van een door g a s t r i n e 
g e s t i m u l e e r d e c a l c i t o n i n e p r o d u c t i e v a n u i t de s c h i l d k l i e r , maar 
van e c t o p i s c h e s e c r e t i e van c a l c i t o n i n e door de tumoren. 
C.B.H. Lamers, W.H.L. Hackeng, Th. Thien, J.H.M, van Tongeren (1980) 
Serum concentrations of immunoreactive calcitonin in patients with hyper-
gastnnaemia. (in press) 
9 
Het Na -K ATPase g e h a l t e i n e r y t h r o c y t e n van p a t i ë n t e n met 
e s s e n t i ë l e h y p e r t e n s i e i s normaal . 
H. Swarts, S.L. Bonting, J . J . de Pont, F. Schuurmans Stekhoven, Th. Thien, 
and A. van ' t Laar (1980) Cation fluxes and Na -К -activated ATPase 
act ivi ty in erythrocytes of patients with essential hypertension. 
(in bewerking) 
10 
De u r i n e i n c o n t i n e n t i e , d i e soms voorkomt t i j d e n s h e t g e b r u i k 
van h e t a n t i h y p e r t e n s i v u m p r a z o s i n e , w i j s t e r o p d a t d i t midde l 
een α - s y m p a t h i c o l y t i c u m i s . 
Th. Thien, K.P.J. Delaere, F.M.J. Debruyne, R.A.P. Koene (1978) Urinary 
incontinence caused by prazosin. Bri t . Med. J . 1, 622. 
1 1 
"Auto-immuunovariitis" kan de oorzaak zi^n van amenorrhoe. 
Th. Thien, H.A.M. de Rooy, W.H.M. v .d . Velden (1974) Ovarian f a i l u r e and 
autoimmunity. Europ. J . Obste t . Gynec. Reprod. B i o l . , 4/1 suppl . S203. 
12 
Een betrouwbare en object ieve maat voor de wetenschappelijke 
a c t i v i t e i t e n van een u n i v e r s i t a i r medewerker v e r k r i j g t men door 
eenvoudigweg z i jn pub l i ca t i e s in wetenschappelijke t i j d s c h r i f t e n 
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